WO1999035293A2 - Solid phase selection of differentially expressed genes - Google Patents
Solid phase selection of differentially expressed genes Download PDFInfo
- Publication number
- WO1999035293A2 WO1999035293A2 PCT/US1999/000666 US9900666W WO9935293A2 WO 1999035293 A2 WO1999035293 A2 WO 1999035293A2 US 9900666 W US9900666 W US 9900666W WO 9935293 A2 WO9935293 A2 WO 9935293A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polynucleotides
- population
- tag
- microparticles
- dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
Definitions
- the invention relates generally to methods for identifying differentially expressed genes, and more particularly, to a method of competitively hybridizing differentially expressed DNAs with reference DNA sequences cloned on solid phase supports to provide a differential expression library which can be physically manipulated, e.g. by fluorescence-activated flow sorting.
- the desire to decode the human genome and to understand the genetic basis of disease and a host of other physiological states associated differential gene expression has been a key driving force in the development of improved methods for analyzing and sequencing DNA, Adams et al., Editors, Automated DNA Sequencing and Analysis (Academic Press, New York, 1994).
- the human genome is estimated to contain about 10 5 genes, 15-30% of which—or about 20-40 megabases ⁇ are active in any given tissue.
- ESTs expressed sequence tags
- SAGE concatenated fragments of expressed sequences
- Velculescu et al. Science, 270: 484-486 (1995); Zhang et al., Science, 276: 1268-1272 (1997); Velculescu et al., Cell, 88: 243-251 (1997); and the use of microarrays of oligonucleotides or polynucleotides for capturing complementary polynucleotides from expressed genes, e.g.
- objects of our invention include, but are not limited to, providing a method for identifying and isolating differentially expressed genes; providing a method of identifying and isolating polynucleotides on the basis of labels that generate different optical signals; providing a method for profiling gene expression of large numbers of genes simultaneously; providing a method of identifying and separating genes in accordance with whether their expression is increased or decrease under any given conditions; providing a method for identifying rare genes; and providing a method for massively parallel signature sequencing of large numbers of genes isolated according to their expression.
- Our invention accomplishes these and other objects by providing differently labeled populations of polynucleotides from cell or tissue sources whose gene expression is to be compared.
- differently labeled polynucleotides of a plurality of populations are competitively hybridized with reference DNA cloned on solid phase supports.
- the solid phase supports are microparticles which, after such competitive hybridization, provide a differential expression library which may be manipulated by fluorescence-activated cell sorting (FACS), or other sorting means responsive to optical signals generated by labeled polynucleotides on the microparticles.
- FACS fluorescence-activated cell sorting
- Monitoring the relative signal intensity of the different labels on the microparticles permits quantification of the relative expression of particular genes in the different populations.
- populations of microparticles having relative signal intensities of interest are isolated by FACS and the attached polynucleotides are sequenced to determine the identities of the rare or differentially expressed genes.
- the method of the invention is carried out by the following steps: a) providing a reference population of nucleic acid sequences attached to separate solid phase supports in clonal subpopulations; b) providing a population of polynucleotides of expressed genes from each of the plurality of different cells or tissues, the polynucleotides of expressed genes from different cells or tissues having a different light-generating label; c) competitively hybridizing the populations of polynucleotides of expressed genes from each of the plurality of different cells or tissues with the reference population to form duplexes between the sequences of the reference population and polynucleotides of each of the different cells or tissues such that the polynucleotides are present in duplexes on each of the solid phase supports in ratios directly related to the relative expression of their
- the method includes the step of sorting each solid phase support according to the relative optical signal detected.
- the reference population of nucleic acids is derived from genes of the plurality of different cells or tissues being analyzed.
- the phrase "polynucleotides of expressed genes" is meant to include any RNA produced by transcription, including in particular mRNA, and DNA produced by reverse transcription of any RNA, including in particular cDNA produced by reverse transcription of mRNA.
- the present invention overcomes shortcoming in the art by providing compositions, methods, and kits for separating and identifying genes that are differentially expressed without requiring any previous analysis or knowledge of the sequences.
- the invention also permits differentially regulated genes to be separated from unregulated genes for analysis, thereby eliminating the need to analyze large numbers of unregulated genes in order to obtain information on the genes of interest.
- Figures la and lb illustrate FACS analysis of microparticles loaded with competitively hybridized DNA strands labeled with two different fluorescent dyes.
- Figure 2 is a schematic representation of a flow chamber and detection apparatus for observing a planar array of microparticles loaded with restriction fragments for sequencing.
- Figure 3 a illustrates a preferred scheme for converting isolated messenger RNA (mRNA) into cDNA and insertion of the cDNA into a tag-containing vector.
- mRNA messenger RNA
- Figure 3b illustrates a preferred scheme for amplifying tag-cDNA conjugates out of a vector and loading the amplified conjugates onto microparticles.
- Figure 3 c illustrates a preferred scheme for isolating sorted cDNAs for cloning and sequencing.
- Figure 4a and 4b illustrate alternative procedures for cloning differentially expressed cDNAs isolated by FACS sorting.
- Figures 5a-e illustrate flow analysis data of microparticles carrying predetermined ratios of two differently labeled cDNAs.
- Figure 6 illustrates flow analysis data of microparticles carrying differently labeled cDNAs from stimulated and unstimulated THP-1 cells.
- Figure 7 illustrates flow analysis data of microparticles carrying labeled cDNAs derived from mRNA of low abundance in stimulated THP-1 cells.
- Figure 8 illustrates flow analysis data of microparticles carrying labeled cDNAs derived from mRNA of low abundance in human bone marrow.
- Figure 9 illustrates flow analysis data of microparticles carrying differently labeled cDNAs from glucose normal and glucose starved muscle tissue.
- Figure 10A illustrates an embodiment of the invention for constructing a reference nucleic acid population on microparticles.
- Figure 10B illustrates an embodiment for using the reference library of Figure 10A to compare gene expression of two cell populations.
- oligonucleotide tags refers to an oligonucleotide to which a oligonucleotide tag specifically hybridizes to form a perfectly matched duplex or triplex.
- the oligonucleotide tag may be selected to be either double stranded or single stranded.
- the term "complement” is meant to encompass either a double stranded complement of a single stranded oligonucleotide tag or a single stranded complement of a double stranded oligonucleotide tag.
- oligonucleotide includes linear oligomers of natural or modified monomers or linkages, including deoxyribonucleosides, ribonucleosides, anomeric forms thereof, peptide nucleic acids (PNAs), and the like, capable of specifically binding to a target polynucleotide by way of a regular pattern of monomer-to-monomer interactions, such as Watson-Crick type of base pairing, base stacking, Hoogsteen or reverse Hoogsteen types of base pairing, or the like.
- monomers are linked by phosphodiester bonds or analogs thereof to form oligonucleotides ranging in size from a few monomeric units, e.g.
- oligonucleotide 3-4, to several tens of monomeric units, e.g. 40-60.
- ATGCCTG a sequence of letters, such as "ATGCCTG”
- A denotes deoxyadenosine
- C denotes deoxycytidine
- G denotes deoxyguanosine
- T denotes thymidine, unless otherwise noted.
- oligonucleotides of the invention comprise the four natural nucleotides; however, they may also comprise non-natural nucleotide analogs.
- oligonucleotides having natural or non- natural nucleotides may be employed, e.g. where processing by enzymes is called for, usually oligonucleotides consisting of natural nucleotides are required.
- Perfectly matched in reference to a duplex means that the poly- or oligonucleotide strands making up the duplex form a double stranded structure with one other such that every nucleotide in each strand undergoes Watson-Crick basepairing with a nucleotide in the other strand.
- the term also comprehends the pairing of nucleoside analogs, such as deoxyinosine, nucleosides with 2-aminopurine bases, and the like, that may be employed.
- the term means that the triplex consists of a perfectly matched duplex and a third strand in which every nucleotide undergoes Hoogsteen or reverse Hoogsteen association with a basepair of the perfectly matched duplex.
- a "mismatch" in a duplex between a tag and an oligonucleotide means that a pair or triplet of nucleotides in the duplex or triplex fails to undergo Watson-Crick and/or Hoogsteen and/or reverse Hoogsteen bonding.
- nucleoside includes the natural nucleosides, including 2'- deoxy and 2'-hydroxyl forms, e.g. as described in Kornberg and Baker, DNA Replication, 2nd Ed. (Freeman, San Francisco, 1992).
- Analogs in reference to nucleosides includes synthetic nucleosides having modified base moieties and/or modified sugar moieties, e.g. described by Scheit, Nucleotide Analogs (John Wiley, New York, 1980); Uhlman and Peyman, Chemical Reviews, 90: 543-584 (1990), or the like, with the only proviso that they are capable of specific hybridization.
- sequence determination or "determining a nucleotide sequence” in reference to polynucleotides includes determination of partial as well as full sequence information of the polynucleotide. That is, the term includes sequence comparisons, fingerprinting, and like levels of information about a target polynucleotide, as well as the express identification and ordering of nucleosides, usually each nucleoside, in a target polynucleotide. The term also includes the determination of the identification, ordering, and locations of one, two, or three of the four types of nucleotides within a target polynucleotide.
- sequence determination may be effected by identifying the ordering and locations of a single type of nucleotide, e.g. cytosines, within the target polynucleotide "CATCGC " so that its sequence is represented as a binary code, e.g. "100101 ... " for "C-(not C)-(not C)-C-(not C)-C ... " and the like.
- a single type of nucleotide e.g. cytosines
- the term “complexity” in reference to a population of polynucleotides means the number of different species of polynucleotide present in the population.
- the term “relative gene expression” or “relative expression” in reference to a gene refers to the relative abundance of the same gene expression product, usually an mRNA, in different cells or tissue types. DETAILED DESCRIPTION OF THE INVENTION The present invention provides compositions, methods, and kits for analyzing relative gene expression in a single or plurality of cell and/or tissue types that are of interest.
- the methods of the invention can be applied to polynucleotides derived from animals, plants, and microorganisms such as fungi, bacteria, mycoplasma, cyanobacteria, algae, and the like.
- the polynucleotides are derived from animals, plants or microorganisms involved in fermentation process, with vertebrates and agricultural plants being most preferred.
- the plurality usually comprises a pair of cell or tissue types, such as a diseased tissue or cell type and a healthy tissue or cell type, or such as a cell or tissue type being subjected to a stimulus or stress, e.g. a change of nutrients, temperature, or the like, and the corresponding cell or tissue type in an unstressed or unstimulated state.
- the plurality can comprise a pair of cell or tissue types having homologous genes, such as cells or tissue from different organisms.
- the plurality may also include more than two cell or tissue types, such as would be required in a comparison of expression patterns of the same cell or tissue over time, e.g. liver cells after exposure of an organism to a candidate drug, organ cells of a test animal at different developmental states, and the like.
- the plurality is 2 or 3 cell or tissue types; and more preferably, it is 2 cell or tissue types.
- the method of the invention typically comprises providing a reference population of nucleic acid sequences attached to separate solid phase supports in clonal subpopulations, providing at least one population of polynucleotides of expressed genes, hybridizing the population(s) of polynucleotides of expressed genes with the reference nucleic acid population, and detecting, and preferably sorting each solid phase support according to a relative optical signal generated by the duplexes attached thereto.
- FIG 10A illustrates an embodiment of the invention for constructing a reference nucleic acid population on microparticles
- Figure 10B illustrates an embodiment for using such a reference library to compare gene expression of two cell populations.
- Messenger RNA (mRNA) is extracted (1004) from cell populations (1000) and (1002) using conventional protocols to give two populations of polynucleotides (1006) and (1008), respectively.
- the extraction reactions can be carried out separately or on a mixture of cell types. Preferably, the reactions are carried out separately so that the relative quantities of mRNA from the two populations can be more readily controlled.
- mRNA (1006) and mRNA (1008) are combined (1010) and cDNA library (1012) is constructed in vectors carrying a repertoire of oligonucleotide tags, in accordance with the procedure described in Brenner et al., U.S. patent 5,846,719.
- mRNA i.e., equal molar quantities
- a sample of vectors from library (1012) is taken and amplified, e.g. by polymerase chain reaction, transfection and cloning, or the like, after which the tag-cDNA conjugates (1014) carried by the vectors are excised or copied (1011) and then isolated.
- Loaded microparticles are then formed and prepared for use in competitive hybridization as follows (1018).
- the isolated tag-cDNA conjugates (1014), illustrated with oligonucleotide tags a, b, c, and d, are specifically hybridized to microparticles carrying their tag complements a', b', c', and d' (1016), respectively.
- the tag-cDNA conjugates are ligated to tag complements so that at least one strand of the double stranded tag-cDNA conjugate is covalently attached to the microparticle.
- Microparticles carrying tag-cDNA conjugates are separated from those that do not carry tag-cDNA conjugates, preferably using a fluorescence-activated cell sorter (FACS), or like instrument.
- FACS fluorescence-activated cell sorter
- the non-covalently attached strand is melted off and separated from the microparticles to yield microparticles (1020) carrying a reference nucleic acid population.
- gene expression of cells (1050) may be compared to that of cells (1052) by separately extracting (1054) mRNA (1056) and (1058) from each cell type.
- mRNA (1056) and (1058) from each cell type.
- single stranded nucleic acid probes are generated from the respective cDNA populations (1062) and (1064), the probes preferably being labeled with optically distinguishable fluorescent dyes F (1068) and R (1066), e.g., rhodamine and fluorescein.
- Equal amounts of the labeled polynucleotides are mixed and hybridized (1072) to the complementary strands carried by the microparticles to form duplexes (1074).
- microparticles carrying the duplexes thereby formed (1074) can be sorted (1076) in accordance to predetermined criteria, such as fluorescence ratio, fluorescence intensity, and/or the like.
- predetermined criteria such as fluorescence ratio, fluorescence intensity, and/or the like.
- subpopulations of interest can be isolated and further analyzed, e.g., those corresponding to up-regulated or down-regulated genes.
- messenger RNA is extracted from the cells or tissues of interest using conventional protocols, as disclosed in, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition (Cold Spring Harbor Laboratory, New York).
- the populations of mRNAs to be compared are converted into populations of labeled cDNAs by reverse transcription in the presence of a labeled nucleoside triphosphate using conventional protocols, e.g. Schena et al., Science 270: 467-470 (1995); DeRisi et al., Science 278: 680-686 (1997); or the like, prior to hybridization to a reference DNA population.
- a labeled nucleoside triphosphate e.g. Schena et al., Science 270: 467-470 (1995); DeRisi et al., Science 278: 680-686 (1997); or the like.
- An important feature of the invention is that the genes whose expression levels change or are different than those of the other cells or tissues being examined may be analyzed separately from those that are not regulated or otherwise altered in response to whatever stress or condition is being studied.
- gene products from the cells or tissues of interest are competitively hybridized with a reference population consisting of DNA sequences attached in clonal subpopulations to separate microparticles.
- microparticles carrying labeled gene products in ratios indicating differential expression may be manipulated and analyzed separately from those carrying labeled gene products in ratios indicating no change in expression, e.g. "house-keeping" genes, genes encoding structural proteins, or the like.
- nucleic acid being analyzed e.g., genomic DNA or gene products such as cDNA, mRNA, RNA transcript, or the like
- identity of the nucleic acid being analyzed e.g., genomic DNA or gene products such as cDNA, mRNA, RNA transcript, or the like
- cDNAs derived from expressed genes may be identified by direct sequencing on the solid phase support, preferably a microparticle, using a number of different sequencing approaches. For identification, only a portion of the cDNAs need be sequenced. In many cases, the portion may be as small as nine or ten nucleotides, e.g. Velculescu et al. (cited above).
- entire subpopulations of differentially expressed genes are sequenced simultaneously using MPSS, or a similar parallel analysis technique.
- this is conveniently accomplished by providing a reference population of DNA sequences such that each such sequence is attached to a separate microparticle in a clonal subpopulation.
- clonal subpopulation refers to multiple copies of a single kind of polynucleotide selected from a population of interest, such as a cDNA library constructed from mRNA extracted from a cell or tissue whose gene expression is being analyzed.
- a population of interest such as a cDNA library constructed from mRNA extracted from a cell or tissue whose gene expression is being analyzed.
- Such clonal subpopulations may be formed in a number of ways, including by separate amplification of a poynucleotide and attacment by conventional attachment chemistries, e.g., Hermansen, Bioconjugate Techniques (Academic Press, New York, 1996).
- clonal subpopulations are preferably formed by so-called "solid phase cloning" disclosed in Brenner, U.S. patent 5,604,097 and Brenner et al., U.S. patent 5,846,719, which are inco ⁇ orated herein by reference. Briefly, such clonal subpopulations are formed by hybridizing an amplified sample of tag-DNA conjugates onto one or more solid phase support(s), e.g., separate and unconnected microparticles, so that individual microparticles, or different regions of a larger support, have attached multiple copies of the same DNA.
- solid phase support(s) e.g., separate and unconnected microparticles
- the DNA component of the tag-DNA conjugate can be cDNA, genomic DNA, a fragment of cDNA or genomic DNA, or a synthetic DNA, such as, for example, an oligonucleotide.
- the tag-DNA conjugate is a cDNA or a fragment of genomic DNA ("gDNA").
- the number of copies of a cDNA or gDNA in a clonal subpopulation may vary widely in different embodiments depending on several factors, including the density of tag complements on the solid phase supports, the size and composition of microparticle used, the duration of hybridization reaction, the complexity of the tag repertoire, the concentration of individual tags, the tag-DNA sample size, the labeling means for generating optical signals, the particle sorting means, signal detection system, and the like.
- the number of copies of a cDNA or a gDNA in a clonal subpopulation is sufficient to permit FACS detection and/or sorting of microparticles, wherein fluorescent signals are generated by one or more fluorescent dye molecules carried by the cDNAs attached to the microparticles.
- this number can be as low as a few thousand, e.g. 3,000-5,000, when a fluorescent molecule such as fluorescein is used, and as low as several hundred, e.g.
- clonal subpopulations consist of at least IO 4 copies of a cDNA or gDNA; and most preferably, in such embodiments, clonal subpopulations consist of at least IO 5 copies ofa cDNA or gDNA.
- Labeled cDNAs or RNAs from the cells or tissues to be compared are competitively hybridized to the DNA sequences of the reference DNA population using conventional hybridization conditions, e.g. such as disclosed in Schena et al. (cited above); DeRisi et al. (cited above); or Shalon, Ph.D. Thesis entitled "DNA Microarrays," Stanford University (1995). After hybridization, an optical signal is generated by each of the two labeled species of cDNAs or RNAs so that a relative optical signal is determined for each microparticle.
- such optical signals are generated and measured in a fluorescence activated cell sorter, or like instrument, which permits the microparticles to be sorted and accumulated whose relative optical signal fall with a predetermined range of values.
- the microparticles loaded with cDNAs or RNAs generating relative optical signals in the desired range may be isolated and identified by sequencing, such as with MPSS, as described more fully below.
- mRNA (300) is extracted from a cell or tissue source of interest using conventional techniques and is converted into cDNA (309) with ends appropriate for inserting into vector (316).
- primer (302) having a 5' biotin (305) and poly(dT) region (306) is annealed to mRNA strands (300) so that the first strand of cDNA (309) is synthesized with a reverse transcriptase in the presence of the four deoxyribonucleoside triphosphates.
- cDNA (309) is hemi-methylated, except for the region corresponding to primer (302).
- primer (302) is not critical to the invention and other molecular capture techniques, or moieties, can be used, e.g. triplex capture, or the like.
- Region (303) of primer (302) preferably contains a sequence of nucleotides that results in the formation of restriction site r 2 (304) upon synthesis of the second strand of cDNA (309).
- cDNA (309) is preferably cleaved with a restriction endonuclease which is insensitive to hemimethylation (of the Cs) and which recognizes site ri (307).
- a restriction endonuclease which is insensitive to hemimethylation (of the Cs) and which recognizes site ri (307).
- is a four-base recognition site e.g. corresponding to Dpn II, or like enzyme, which ensures that substantially all of the cDNAs are cleaved and that the same defined end is produced in all of the cDNAs.
- fragment (308) is purified using standard techniques, e.g. ethanol precipitation, polyacrylamide gel electrophoresis, or the like. After resuspending in an appropriate buffer, fragment (308) is directionally ligated into vector (316), which carries tag (310) and a cloning site with ends (312) and (314).
- vector (316) is prepared with a "stuffer" fragment in the cloning site to aid in the isolation of a fully cleaved vector for cloning.
- cDNA can be prepared by conventional methods and isolated by gel electrophoresis. This method is less preferred in part because it would bias the size distribution of the reference population.
- the tag can be attached by ligation of adaptors, by PCR with an oligo dT primer and a random primer, or by RACE technology (Bertling et al. (1993) PCR Methods Appl. 3:95-99; Frohman, M.A. (1993) Methods Enzymol. 218:340-356; MarathonTM CDNA Amplification Kit, Clontech Laboratories, Inc.).
- Attachment of the tag by cloning into a vector is preferred for several reasons, including the ability to generate large quantities of the reference population (versus RACE, which typically yields only ⁇ g quantities), and the ability to check the sequence of the tag.
- a sample of host cells is usually plated to determine the number of recombinants per unit volume of culture medium. The size of sample taken for further processing preferably depends on the size of tag repertoire used in the library construction. As taught by Brenner et al., U.S. patent 5,846,719 and Brenner et al., U.S.
- a sample preferably includes a number of conjugates equivalent to about one percent the size of the tag repertoire in order to minimize the selection of "doubles," i.e. two or more conjugates carrying the same tag and different cDNAs.
- doubles i.e. two or more conjugates carrying the same tag and different cDNAs.
- the size of the repertoire is 8 , or about 1.7 x 10 tags. Accordingly, with such a repertoire, a sample of about 1.7 x 10 5 conjugate-containing vectors is preferably selected for amplification and further processing as illustrated in Figure 3b.
- tag-cDNA conjugates are carried in vector (330) which comprises the following sequence of elements: first primer binding site (332), restriction site r (334), oligonucleotide tag (336), junction (338), cDNA (340), restriction site r 4 (342), and second primer binding site (344).
- first primer binding site 332
- restriction site r 334
- oligonucleotide tag 336
- junction 338
- cDNA 340
- restriction site r 4 restriction site r 4
- second primer binding site 344
- the tag- cDNA conjugates are preferably amplified from vector (330) by use of biotinylated primer (348) and labeled primer (346) in a conventional polymerase chain reaction (PCR) in the presence of 5 -methyldeoxycytidine triphosphate, after which the resulting amplicon is isolated by streptavidin capture.
- PCR polymerase chain reaction
- Restriction site r 3 preferably corresponds to a rare-cutting restriction endonuclease, such as Pac I, Not I, Fse I, Pme I, Swa I, or the like, which permits the captured amplicon to be release from a support with minimal probability of cleavage occurring at a site internal to the cDNA of the amplicon.
- Junction (338) which is illustrated as the sequence:
- the DNA polymerase "stripping" reaction causes the DNA polymerase "stripping" reaction to be halted at the G triplet, when an appropriate DNA polymerase is used with dGTP.
- the 3' ⁇ 5' exonuclease activity of a DNA polymerase preferably T4 DNA polymerase, is used to render the tag of the tag-cDNA conjugate single stranded, as taught by Brenner, U.S. patent 5,604,097; and Kuijper et al, Gene, 112: 147-155 (1992).
- tags of tag-cDNA conjugates are rendered single stranded by first selecting words that contain only three of the four natural nucleotides, and then by preferentially digesting the three nucleotide types from the tag-cDNA conjugate in the 3'-»5' direction with the 3' ⁇ 5' exonuclease activity of a DNA polymerase.
- oligonucleotide tags are designed to contain only A's, G's, and T's; thus, tag complements (including that in the double stranded tag-cDNA conjugate) consist of only A's, Cs, and T's.
- steps (358) are implemented: the tag- cDNA conjugates are hybridized to tag complements attached to microparticles, a fill- in reaction is carried out to fill any gap between the complementary strand of the tag- cDNA conjugate and the 5' end of tag complement (362) attached to microparticle (360), and the complementary strand of the tag-cDNA conjugate is covalently bonded to the 5' end (363) of tag complement (362) by treating with a ligase.
- This embodiment requires, of course, that the 5' end of the tag complement be phosphorylated, e.g. by a kinase, such as, T4 polynucleotide kinase, or the like.
- the fill-in reaction is preferably carried out because the "stripping" reaction does not always halt at the first G.
- the fill-in reaction uses a DNA polymerase lacking 5'— >3' exonuclease activity and strand displacement activity, such as T4 DNA polymerase.
- all four dNTPs are used in the fill-in reaction, in case the "stripping" extended beyond the G triplet.
- the tag-cDNA conjugates are hybridized to the full repertoire of tag complements. That is, among the population of microparticles, there are microparticles having every tag sequence of the entire repertoire. Thus, the tag-cDNA conjugates will hybridize to tag complements on only about one percent of the microparticles.
- Microparticles to which tag-cDNA have been hybridized are referred to herein as "loaded microparticles.”
- loaded microparticles are preferably separated from unloaded microparticles for further processing. Such separation is conveniently accomplished by use of a fluorescence- activated cell sorter (FACS), or similar instrument that permits rapid manipulation and sorting of large numbers of individual microparticles.
- FACS fluorescence- activated cell sorter
- a fluorescent label e.g. FAM (a fluorescein derivative, Haugland, Handbook of Fluorescent Probes and Research Chemicals, Sixth Edition, (Molecular Probes, Eugene, OR, 1996) is attached by way of primer (346).
- FAM fluorescein derivative, Haugland, Handbook of Fluorescent Probes and Research Chemicals, Sixth Edition, (Molecular Probes, Eugene, OR, 1996)
- the tag-cDNA can be attached to the tag complement on the microparticles by a procedure omitting or modifying many of the steps discussed above. For example, instead of amplifying the tag-cDNA from vector (330), the tag-cDNA can be cleaved from the vector by restriction digest, stripped, and ligated directly to the tag complement on the microparticles. This procedure omits (1) labeling the tag-cDNA with biotin and FAM, (2) amplifying the tag-cDNA, and (3) isolating the amplicon by streptavidin capture. If desired, loaded microparticles can be isolated by hybridizing with a FAM-labeled primer.
- loaded microparticles (360) are isolated, treated to remove label (345), and treated to melt off the non-covalently attached strand.
- Label (345) is removed or inactivated so that it does not interfer with the labels of the competitively hybridized strands.
- the tag-cDNA conjugates are treated with a restriction endonuclease recognizing site ri (342) which cleaves the tag-cDNA conjugates adjacent to primer binding site (344), thereby removing label (345) carried by the "bottom" strand, i.e. the strand have its 5' end distal to the microparticle.
- this cleavage results in microparticle (360) with double stranded tag-cDNA conjugate (384) having protruding strand (385).
- 3'- labeled adaptor (386) is then annealed and ligated to protruding strand (385), after which the loaded microparticles are re-sorted by means of the 3'-label and the strand carrying the 3'-label is melted off to leave a covalently attached single strand of the cDNA (392) ready to accept denatured cDNAs or mRNAs from differentially expressed genes.
- the 3'-labeled strand is melted off with sodium hydroxide treatment, or treatment with like reagent.
- genomic DNA is isolated from a cell or tissue source of interest using conventional techniques and is cleaved with at least one restriction endonuclease, which preferably cleaves at a four-base recognition, such as, for example, Dpn II, Sau3A I, Aci I, Alu I, Bfa I, BstU I, Hae III, Hha I, HinPl I, Hpa II, Mbo I, Mse I, Msp I, Nla III, Rsa I, Taq ⁇ I, Tsp 509 I, and the like.
- the cleaved fragment has an overhang of at least one base.
- genomic DNA fragments can be prepared by shearing or sonicating the isolated genomic DNA.
- the tag can then be linked to the gDNA in a number of ways, including random primed PCR with primers containing the tag sequence or cloning into a vector containing a tag in a manner similar to that described above for a cDNA reference population.
- a label such as FAM can be attached in order to momtor the loading of the microparticles.
- directional attachment onto the microparticles can be achieved by amplifying the gDNA with a primer having a consensus sequence, such as, for example, the TATA box, or a sequence complementary to a consensus sequence.
- a large gDNA library of about 60 x IO 6 microparticles can be reduced to about 30,000-40,000 by culling, using cDNA pools as a probe.
- Oligonucleotide Tags for Identification and Solid Phase Cloning
- An important feature of the invention is the use of oligonucleotide tags which are members of a minimally cross-hybridizing set of oligonucleotides to construct reference DNA populations attached to solid phase supports, preferably microparticles.
- the sequences of oligonucleotides of a minimally cross-hybridizing set differ from the sequences of every other member of the same set by at least two nucleotides. Thus, each member of such a set cannot form a duplex (or triplex) with the complement of any other member with less than two mismatches.
- oligonucleotide tags may comprise natural nucleotides or non-natural nucleotide analogs.
- tag complements are preferably attached to solid phase supports. Oligonucleotide tags when used with their corresponding tag complements provide a means of enhancing specificity of hybridization for sorting, tracking, or labeling molecules, especially polynucleotides, such as cDNAs or mRNAs derived from expressed genes.
- Minimally cross-hybridizing sets of oligonucleotide tags and tag complements may be synthesized either combinatorially or individually depending on the size of the set desired and the degree to which cross-hybridization is sought to be minimized (or stated another way, the degree to which specificity is sought to be enhanced).
- a minimally cross-hybridizing set may consist of a set of individually synthesized 10-mer sequences that differ from each other by at least 4 nucleotides, such set having a maximum size of 332, when constructed as disclosed in Brenner et al., U.S. patent 5,604,097.
- a minimally cross-hybridizing set of oligonucleotide tags may also be assembled combinatorially from subunits which themselves are selected from a mimmally cross-hybridizing set.
- a set of minimally cross-hybridizing 12-mers differing from one another by at least three nucleotides may be synthesized by assembling 3 subunits selected from a set of mimmally cross-hybridizing 4-mers that each differ from one another by three nucleotides.
- Such an embodiment gives a maximally sized set of 9 3 , or 729, 12-mers.
- an oligonucleotide tag can be randomized at individual positions along its length.
- the oligonucleotide tag consists of a plurality of subunits, each subunit consisting of an oligonucleotide of 3 to 9 nucleotides in length wherein each subunit is selected from the same minimally cross-hybridizing set.
- the number of oligonucleotide tags available depends on the number of subunits per tag and on the length of the subunits.
- An oligonucleotide tag can also consist of a plurality of subunits with additional nucleotides on either terminus of the oligonucleotide. The additional nucleotides can be random and/or can comprise a restriction site.
- the oligonucleotide comprises a recognition site for a rare-cutting restriction endonuclease on at least one end.
- the oligonucleotide comprises an AT-rich restriction site, such as a Pac I site, on one end.
- a Bspl20 site is a preferred site on the other end.
- Complements of oligonucleotide tags attached to one or more solid phase supports are used to sort polynucleotides from a mixture of polynucleotides each containing a tag.
- tag complements are synthesized on the surface of a solid phase support, such as a bead, preferably microscopic, or a specific location on an array of synthesis locations on a single support, such that populations of identical, or substantially identical, sequences are produced in specific regions. That is, the surface of each support, in the case of a bead, or of each region, in the case of an array, is derivatized by copies of only one type of tag complement having a particular sequence. The population of such beads or regions contains a repertoire of tag complements each with distinct sequences.
- oligonucleotide tags and tag complements means the total number of different oligonucleotide tags or tag complements that are employed for solid phase cloning (sorting) or identification.
- a repertoire may consist of a set of minimally cross-hybridizing set of oligonucleotides that are individually synthesized, or it may consist of a concatenation of oligonucleotides each selected from the same set of mimmally cross-hybridizing oligonucleotides. In the latter case, the repertoire is preferably synthesized combinatorially.
- tag complements are synthesized combinatorially on microparticles, so that each microparticle has attached many copies of the same tag complement.
- microparticle supports may be used with the invention, including microparticles made of controlled pore glass (CPG), highly cross-linked polystyrene, acrylic copolymers, cellulose, nylon, dextran, latex, polyacrolein, and the like, disclosed in the following exemplary references: Meth. Enzymol., Section A, pages 11-147, vol. 44 (Academic Press, New York, 1976); U.S. patents 4,678,814; 4,413,070; and 4,046;720; and Pon, Chapter 19, in Agrawal, editor, Methods in Molecular Biology, Vol.
- CPG controlled pore glass
- Microparticle supports further include commercially available nucleoside-derivatized CPG and polystyrene beads (e.g. available from PE Applied Biosystems, Foster City, CA); derivatized magnetic beads; polystyrene grafted with polyethylene glycol (e.g., TentaGelTM, Rapp Polymere, Tubingen Germany); and the like.
- Microparticles may also consist of dendrimeric structures, such as disclosed by Nilsen et al., U.S. patent 5,175,270.
- the size and shape of a microparticle is not critical; however, microparticles in the size range of a few, e.g.
- GMA glycidal methacrylate
- polynucleotides to be sorted, or cloned onto a solid phase support each have an oligonucleotide tag attached, such that different polynucleotides have different tags.
- This condition is achieved by employing a repertoire of tags substantially greater than the population of polynucleotides and by taking a sufficiently small sample of tagged polynucleotides from the full ensemble of tagged polynucleotides. After such sampling, when the populations of supports and polynucleotides are mixed under conditions which permit specific hybridization of the oligonucleotide tags with their respective complements, identical polynucleotides sort onto particular beads or regions.
- the sampled tag-polynucleotide conjugates are preferably amplified, e.g. by polymerase chain reaction, cloning in a plasmid, RNA transcription, or the like, to provide sufficient material for subsequent analysis.
- Oligonucleotide tags are employed for two different purposes in certain embodiments of the invention: Oligonucleotide tags are employed to implement solid phase cloning, as described in Brenner, U.S. patent 5,604,097; and International patent application PCT/US96/09513, wherein large numbers of polynucleotides, e.g.
- oligonucleotide tags of a mimmally cross-hybridizing set may be separately synthesized, as well as synthesized combinatorially.
- oligonucleotides may be synthesized directly by a variety of parallel synthesis approaches, e.g. as disclosed in Frank et al., U.S. patent 4,689,405; Frank et al., Nucleic Acids Research, 11 : 4365-4377 (1983); Matson et al., Anal. Biochem., 224: 110-116 (1995); Fodor et al., International application PCT/US93/04145; Pease et al., Proc. Natl. Acad. Sci., 91: 5022-5026 (1994); Southern et al., J.
- tag complements in mixtures are selected to have similar duplex or triplex stabilities to one another so that perfectly matched hybrids have similar or substantially identical melting temperatures.
- minimally cross-hybridizing sets may be constructed from subunits that make approximately equivalent contributions to duplex stability as every other subunit in the set. Guidance for carrying out such selections is provided by published techniques for selecting optimal PCR primers and calculating duplex stabilities, e.g.
- a minimally cross- hybridizing set of oligonucleotides can be screened by additional criteria, such as GC- content, distribution of mismatches, theoretical melting temperature, and the like, to form a subset which is also a minimally cross-hybridizing set.
- oligonucleotide tags of the invention and their complements are conveniently synthesized on an automated DNA synthesizer, e.g. an Applied
- Oligonucleotide tags for sorting may range in length from 12 to 60 nucleotides or basepairs. Preferably, oligonucleotide tags range in length from 18 to 40 nucleotides or basepairs. More preferably, oligonucleotide tags range in length from 25 to 40 nucleotides or basepairs. In terms of preferred and more preferred numbers of subunits, these ranges may be expressed as follows:
- oligonucleotide tags for sorting are single stranded and specific hybridization occurs via Watson-Crick pairing with a tag complement.
- repertoires of single stranded oligonucleotide tags for sorting contain at least 100 members; more preferably, repertoires of such tags contain at least 1000 members; and most preferably, repertoires of such tags contain at least 10,000 members.
- the length of single stranded tag complements for delivering labels is between 8 and 20. More preferably, the length is between 9 and 15.
- coding of tag sequences follows the same principles as for duplex-forming tags; however, there are further constraints on the selection of subunit sequences.
- third strand association via Hoogsteen type of binding is most stable along homopyrimidine-homopurine tracks in a double stranded target.
- base triplets form in T-A*T or C-G*C motifs (where "-" indicates Watson-Crick pairing and "*" indicates Hoogsteen type of binding); however, other motifs are also possible.
- Hoogsteen base pairing permits parallel and antiparallel orientations between the third strand (the Hoogsteen strand) and the purine-rich strand of the duplex to which the third strand binds, depending on conditions and the composition of the strands.
- nucleoside type e.g. whether ribose or deoxyribose nucleosides are employed
- base modifications e.g. methylated cytosine, and the like
- Conditions for annealing single-stranded or duplex tags to their single-stranded or duplex complements are well known, e.g.
- flanking regions of the oligonucleotide tag may be engineered to contain restriction sites, as exemplified above, for convenient insertion into and excision from cloning vectors.
- the right or left primers may be synthesized with a biotin attached (using conventional reagents, e.g. available from Clontech Laboratories, Palo Alto, CA) to facilitate purification after amplification and/or cleavage.
- the above library is inserted into a conventional cloning vector, such a pUC19, or the like.
- the vector containing the tag library may contain a "stuffer" region, "XXX ... XXX,” which facilitates isolation of fragments fully digested with, for example, Bam HI and Bbs I.
- An important aspect of the invention is the sorting and attachment of populations of DNA sequences, e.g. from a cDNA library, to microparticles or to separate regions on a solid phase support such that each microparticle or region has substantially only one kind of sequence attached; that is, such that the DNA sequences are present in clonal subpopulations.
- This objective is accomplished by insuring that substantially all different DNA sequences have different tags attached. This condition, in turn, is brought about by taking only a sample of the full ensemble of tag-DNA sequence conjugates for analysis.
- sampling can be carried out either overtly—for example, by taking a small volume from a larger mixture— after the tags have been attached to the DNA sequences; it can be carried out inherently as a secondary effect of the techniques used to process the DNA sequences and tags; or sampling can be carried out both overtly and as an inherent part of processing steps.
- the term "substantially all" in reference to attaching tags to molecules, especially polynucleotides, is meant to reflect the statistical nature of the sampling procedure employed to obtain a population of tag-molecule conjugates essentially free of doubles. Preferably, at least ninety-five percent of the DNA sequences have unique tags attached.
- DNA sequences are conjugated to oligonucleotide tags by inserting the sequences into a conventional cloning vector carrying a tag library.
- cDNAs may be constructed having a Bsp 120 1 site at their 5' ends and after digestion with Bsp 120 1 and another enzyme such as Sau 3 A or Dpn II may be directionally inserted into a pUC19 carrying the tags of Formula I to form a tag-cDNA library, which includes every possible tag-cDNA pairing.
- a sample is taken from this library for amplification and sorting. Sampling may be accomplished by serial dilutions of the library, or by simply picking plasmid-containing bacterial hosts from colonies. After amplification, the tag-cDNA conjugates may be excised from the plasmid.
- the polynucleotides are mixed with microparticles containing the complementary sequences of the tags under conditions that favor the formation of perfectly matched duplexes between the tags and their complements.
- the hybridization conditions are sufficiently stringent so that only perfectly matched sequences form stable duplexes.
- the polynucleotides specifically hybridized through their tags may be ligated to the complementary sequences attached to the microparticles. Finally, the microparticles are washed to remove polynucleotides with unligated and/or mismatched tags.
- Specificity of the hybridizations of tag to their complements may be increased by taking a sufficiently small sample so that both a high percentage of tags in the sample are unique and the nearest neighbors of substantially all the tags in a sample differ by at least two words.
- This latter condition may be met by taking a sample that contains a number of tag-polynucleotide conjugates that is about 0.1 percent or less of the size of the repertoire being employed. For example, if tags are constructed with eight words a repertoire of 8 , or about 1.67 x 10 , tags and tag complements are produced. In a library of tag-DNA sequence conjugates as described above, a 0.1 percent sample means that about 16,700 different tags are present.
- loaded microparticles may be separated from unloaded microparticles by a fluorescence activated cell sorting (FACS) instrument using conventional protocols after DNA sequences have been fluorescently labeled and denatured. After loading and FACS sorting, the label may be cleaved prior use or other analysis of the attached DNA sequences.
- FACS fluorescence activated cell sorting
- a reference DNA population for use in the analysis of gene expression in a plurality of cells or tissues is constructed by generating a cDNA library from each of the cells or tissues whose gene expression is being compared. This may be accomplished either by pooling the mRNA extracted from the various cells and/or tissues, or it may be accomplished by pooling the cDNAs of separately constructed cDNA libraries.
- a reference DNA population may be constructed from genomic DNA. The objective is to obtain a set of DNA sequences that will include all of the sequences that could possibly be expressed in any of the cells or tissues being analyzed. Once the DNA sequences making up a reference DNA population are obtained, they must be conjugated with oligonucleotide tags for solid phase cloning.
- the DNA sequences are prepared so that they can be inserted into a vector carrying an appropriate tag repertoire, as described above, to form a library of tag- DNA sequence conjugates.
- a sample of conjugates is taken from this library, amplified, and loaded onto microparticles. It is important that the sample be large enough so that there is a high probability that all of the different types of DNA sequences are represented on the loaded microparticles. For example, if among a plurality of cells being compared a total of about 25,000 genes are expressed, then a sample of about five-fold this number, or about 125,000 tag-DNA sequence conjugates, should be taken to ensure that all possible DNA sequences will be represented among the loaded microparticles with about a 99% probability, e.g. Sambrook et al. (cited above).
- the reference population can comprise a set of polynucleotides encoding a specific set or sets of proteins selected from the group consisting of cell cycle proteins, signal transduction pathway proteins, oncogene gene products, tumor suppressors, kinases, phosphatases, transcription factors, growth factor receptors, growth factors, extracellular matrix proteins, proteases, cytoskeletal proteins, membrane receptors, Rb pathway proteins, p53 pathway proteins, proteins involved in metabolism, proteins involved in cellular responses to stress, cytokines, proteins involved in DNA damage and repair, and proteins involved in apoptosis.
- proteins selected from the group consisting of cell cycle proteins, signal transduction pathway proteins, oncogene gene products, tumor suppressors, kinases, phosphatases, transcription factors, growth factor receptors, growth factors, extracellular matrix proteins, proteases, cytoskeletal proteins, membrane receptors, Rb pathway proteins, p53 pathway proteins, proteins involved in metabolism, proteins involved in cellular responses to stress, cytokines, proteins involved in DNA damage and repair, and
- Such polynucleotides are typically attached to the solid phase supports through oligonucleotides having a unique sequence per solid support, but such polynucleotides can also be attached to the solid phase supports through an oligonucleotide with a sequence common for each solid phase support, such as, for example a polyadenylated oligonucleotide.
- the tag-DNA sequence conjugates are sampled, they are amplified by PCR using a fluorescently labeled primer to provide sufficient material to load onto the tag complements of the microparticles and to provide a means for distinguishing loaded from unloaded microparticles, as disclosed in Brenner et al. (cited above).
- the PCR primer also contains a sequence which allows the generation of a restriction site of a rare-cutting restriction endonuclease, such as Pac I, in the double stranded product so that the fluorescent label may be cleave from the end of the cDNA prior to the competitive hybridization of labeled DNA strands derived from cells or tissue being studied.
- the specifically hybridized tag-DNA sequence conjugates are ligated to the tag complements and the loaded microparticles are separated from the unloaded microparticles by FACS.
- the fluorescent label is cleaved from the DNA strands of the loaded microparticles and the non-covalently attached strand is removed by denaturing with heat, formamide, NaOH, and/or with like means, using conventional protocols.
- the microparticles are then ready for competitive hybridization.
- Gene expression products e.g. mRNA or cDNA, from the cells and/or tissues being analyzed are isolated.
- the expression products are labeled so as to distinguish the source.
- the products from each source comprise a label different from the label comprised by the products of any other source, e.g., each having a unique and distinguishable emission frequency.
- the product of one source can be left unlabeled.
- the expression products can be labeled by conventional techniques, e.g. DeRisi et al. (cited above), or the like.
- a light-generating label is incorporated into cDNAs reverse transcribed from the extracted mRNA, or an oligonucleotide tag is attached for providing a labeled tag complement for identification.
- a large number of light-generating labels are available, including fluorescent, colorimetric, chemiluminescent, and electroluminescent labels.
- such labels produce an optical signal which may comprise an absorption frequency, an emission frequency, an intensity, a signal lifetime, or a combination of such characteristics.
- fluorescent labels are employed, either by direct incorporation of fluorescently labeled nucleoside triphosphates or by indirect application by incorporation of a capture moiety, such as biotinylated nucleoside triphosphates or an oligonucleotide tag, followed by complexing with a moiety capable of generating a fluorescent signal, such as a streptavidin-fluorescent dye conjugate or a fluorescently labeled tag complement.
- a capture moiety such as biotinylated nucleoside triphosphates or an oligonucleotide tag
- the optical signal detected from a fluorescent label is an intensity at one or more characteristic emission frequencies. Selection of fluorescent dyes and means for attaching or incorporating them into DNA strands is well known, e.g. DeRisi et al. (cited above), Matthews et al, Anal.
- light-generating labels are selected so that their respective optical signals can be related to the quantity of labeled DNA strands present and so that the optical signals generated by different light-generating labels can be compared.
- Measurement of the emission intensities of fluorescent labels is the preferred means of meeting this design objective.
- relating their emission intensities to the respective quantities of labeled DNA strands requires consideration of several factors, including fluorescent emission maxima of the different dyes, quantum yields, emission bandwidths, absorption maxima, absorption bandwidths, nature of excitation light source(s), and the like.
- Guidance for making fluorescent intensity measurements and for relating them to quantities of analytes is available in the literature relating to chemical and molecular analysis, e.g.
- relative optical signal means a ratio of signals from different light-generating labels that can be related to a ratio of differently labeled DNA strands of identical, or substantially identical, sequences that form duplexes with a complementary reference DNA strand.
- a relative optical signal is a ratio of fluorescence intensities of two or more different fluorescent dyes.
- the competitive hybridization conditions are selected so that the proportion of labeled DNA strands forming duplexes with complementary reference DNA strands reflects, and preferably is directly proportional to, the amount of that DNA strand in its population in comparison with the amount of the competing DNA strands of identical sequence in their respective populations.
- first and second differently labeled DNA strands with identical sequence are competing for hybridization with a complementary reference DNA strand such that the first labeled DNA strand is at a concentration of 1 ng ⁇ l and the second labeled DNA strand is at a concentration of 2 ng/ ⁇ l, then at equilibrium it is expected that one third of the duplexes formed with the reference DNA would include first labeled DNA strands and two thirds of the duplexes would include second labeled DNA strands.
- kits for analyzing differentially expressed genes comprising a mixture of microparticles, each microparticle having a population of identical single stranded nucleic acid molecules attached thereto, the single stranded nucleic acid molecules being different on each microparticle and comprising a polynucleotide derived from an mRNA of at least one cell or tissue source.
- each of said nucleic acid molecules further comprises an oligonucleotide tag in juxtaposition with said polynucleotide and positioned between said microparticle and said polynucleotide.
- the kit can further comprise a population of cDNA molecules from at least one of said cell or tissue sources, reagents for labeling the cDNA populations, reagents for performing competitive hybridization, and the like. If desired, the cDNA molecules in the kit are provided in fluorescently labeled form.
- the kit can contain additional components for performing competitive hybridization, such as, for example, hybridization buffers, PCR buffers and standards, and the like.
- the kit can further comprise at least one container or several containers for each of the components and can comprise printed instructions for use in analyzing differentially expressed genes.
- the invention also provides a kit for preparing a reference population, comprising a plurality of microparticles having oligonucleotide tag complements attached thereto, the oligonucleotide tag complement sequence being different on each microparticle.
- the kit can further comprise a plurality of vectors comprising a library of tags having sequences complementary to the tag complements.
- the kit can further comprise a population of polynucleotides from at least one cell or tissue source, preferably cDNAs. When a population of polynucleotides is included, preferably the population of polynucleotides is contained in a container separate from said plurality of microparticles.
- the kit can also contain reagents for preparing the reference population, such as, for example, adaptors, labels, polymerase, dNTP's, labelled dNTP's, PCR buffers, and the like, as well as printed instructions for preparing the reference population.
- reagents for preparing the reference population such as, for example, adaptors, labels, polymerase, dNTP's, labelled dNTP's, PCR buffers, and the like, as well as printed instructions for preparing the reference population.
- microparticles may be analyzed and/or sorted in a number of ways depending on the chemical and/or physical properties of the microparticles and the attached sequences.
- microparticles of interest may be mechanically separated by micro-manipulators
- magnetic microparticles may be sorted by adjusting or manipulating magnetic fields
- charged microparticles may be manipulated by electrophoresis, or the like.
- the following references provide guidance for selecting means for analyzing and/or sorting microparticles: Pace, U.S.
- Patent 4,908,112 Saur et al., U.S. Patent 4,710,472; Senyei et al., U.S. Patent 4,230,685; Wilding et al., U.S. Patent 5,637,469; Penniman et al., U.S. Patent 4,661,225; Karnaukhov et al., U.S. Patent 4,354,114; Abbott et al., U.S. Patent 5,104,791 ; Gavin et al., PCT publication WO 97/40383; and the like.
- microparticles containing fluorescently labeled DNA strands are conveniently classified and sorted by a commercially available FACS instrument, e.g.
- the FACS instrument has multiple fluorescent channel capabilities.
- each microparticle upon excitation with one or more high intensity light sources, such as a laser, a mercury arc lamp, or the like, each microparticle will generate fluorescent signals, usually fluorescence intensities, related to the quantity of labeled DNA strands from each cell or tissue types carried by the microparticle.
- fluorescent intensities of each microparticle are plotted on a two-dimensional graph, microparticles indicating equal expression levels will be on or near the diagonal (100) of the graph. Up-regulated and down-regulated genes will appear in the off-diagonal regions (112).
- Such microparticles are readily sorted by commercial FACS instruments by graphically defining sorting parameters to enclose one or both off-diagonal regions (112) as shown in Figure lb.
- microparticles can be sorted according to their relative optical signal, and if desired, collected for further analysis by accumulating those microparticles generating a signal within a predetermined range of values corresponding to a difference in gene expression among the different cell or tissue sources.
- Microparticles containing fluorescently labeled DNA strands can also be classified and sorted according to the abundance of the gene products from which they are derived.
- the abundance of a nucleic acid sequence can be determined by the methods described above for determining relative gene expression and can be correlated with the level of intensity of the optical signal generated by the polynucleotides bound to the microparticles. A lower intensity is indicative of a rarer nucleic acid sequence, such as a rare gene product.
- Rare genes are genes encoding an mRNA which is present in about 100 copies per cell or less, with increasing preference for less than about 50 copies to less than about 25 copies, with less than about 10 copies per cell being most preferred. Rare genes can be isolated by collecting microparticles with low fluorescent intensities as shown in Examples 9 and 10. The collected microparticles typically comprise less than about 5% of the total microparticles, with increasing preference for less than about 2.5%, 1%, to 0.5% with less than about 0.1 % being most preferred.
- hybridization rates are proportionate to the abundance of a nucleic acid sequence
- less abundant nucleic acid sequences can be isolated by setting the hybridization conditions such that nucleic acid sequences present in a lower abundance in a cell or tissue source remain unhybridized.
- Suitable hybridization conditions include those conditions used for producing normalized cDNA libraries (Patanjali et al., Proc. Natl. Acad. Sci. USA, 88:1943-1947 (1991)).
- rare genes can be isolated by collecting unhybridized DNA after allowing a maximum period of time for hybridization of the abundant DNA species.
- Repetitive sequences can often complicate the mapping and analysis of polymorphisms. Repetitive sequences exist due to the presence in the genome of transposons, retrotransposons, retroviruses, short interspersed repetitive elements (SINEs) such as Alu sequences, satellite DNA, minisatellite DNA, megasatellite DNA, and the like. Repetitive sequences can be removed from a DNA population as described above by sorting rapidly hybridizing DNA species away from DNA species that are slower to hybridize. Preferably, the unhybridized population is substantially enriched in polynucleotides derived from non-repetitive nucleic acid sequences.
- SINEs short interspersed repetitive elements
- Another aspect of the invention is a kit for analyzing and/or isolating nucleic acid sequences with respect to their abundance comprising microparticles prepared as described above and printed instructions for use.
- Identification of Sorted Genes by Massively Parallel Signature Sequencing flVTPSS ⁇ l Expressed genes may be identified in parallel by MPSS, which is a combination of two techniques: one for tagging and sorting fragments of DNA for parallel processing (e.g. Brenner et al., International application PCT US96/09513), and another for the stepwise sequencing the end of a DNA fragment (e.g. Brenner, U.S. patent 5,599,675 and Albrecht et al., International patent application PCT/US97/09472).
- restriction fragments are ligated to oligonucleotide tags as described below, and in Brenner et al., International application PCT/US96/09513, so that the resulting tag-fragment conjugates may be sampled, amplified, and sorted onto separate solid phase supports by specific hybridization of the oligonucleotide tags with their tag complements.
- the ends of the fragments are preferably sequenced with an adaptor-based method of DNA sequencing that includes repeated cycles of ligation, identification, and cleavage, such as the method described in Brenner, U.S. patent 5,599,675.
- adaptors used in the sequencing method each have a protruding strand and an oligonucleotide tag selected from a minimally cross-hybridizing set of oligonucleotides, as taught by Albrecht et al., International patent application PCT/US97/09472.
- Encoded adaptors Such adaptors are referred to herein as “encoded adaptors.” Encoded adaptors whose protmding strands form perfectly matched duplexes with the complementary protmding strands of a fragment are ligated. After ligation, the identity and ordering of the nucleotides in the protmding strand is determined, or "decoded,” by specifically hybridizing a labeled tag complement, or "de-coder" to its corresponding tag on the ligated adaptor.
- the preferred sequencing method is carried out with the following steps: (a) ligating an encoded adaptor to an end of a fragment, the encoded adaptor having a nuclease recognition site of a nuclease whose cleavage site is separate from its recognition site; (b) identifying one or more nucleotides at the end of the fragment by the identity of the encoded adaptor ligated thereto; (c) cleaving the fragment with a nuclease recognizing the nuclease recognition site of the encoded adaptor such that the fragment is shortened by one or more nucleotides; and (d) repeating said steps (a) through (c) until said nucleotide sequence of the end of the fragment is determined.
- successive sets of tag complements are specifically hybridized to the respective tags carried by encoded adaptors ligated to the ends of the fragments.
- the type and sequence of nucleotides in the protmding strands of the polynucleotides are identified by the label carried by the specifically hybridized de-coder and the set from which the de-coder came, as described below.
- Gene products carried by microparticles may be identified after sorting, e.g. by FACS, using conventional DNA sequencing protocols. Suitable templates for such sequencing may be generated in several different ways starting from the sorted microparticles carrying differentially expressed gene products.
- the reference DNA attached to an isolated microparticle may be used to generate labeled extension products by cycle sequencing, e.g. as taught by Brenner, International application PCT US95/12678.
- primer binding site (400) is engineered into the reference DNA (402) distal to tag complement (406), as shown in Figure 4a. After isolating a microparticle, e.g.
- sequencing templates may be produced without sorting individual microparticles.
- Primer binding sites (400) and (420) may be used to generate templates by PCR using primers (404) and (422).
- the resulting amplicons containing the templates are then cloned into a conventional sequencing vector, such as Ml 3. After transfection, hosts are plated and individual clones are selected for sequencing.
- primer binding site (412) may be engineered into the competitively hybridized strands (410). This site need not have a complementary strand in the reference DNA (402).
- competitively hybridized strands (410) are melted off of reference DNA (402) and amplified, e.g. by PCR, using primers (414) and (416), which may be labeled and/or derivatized with biotin for easier manipulation.
- the melted and amplified strands are then cloned into a conventional sequencing vector, such as M13, which is used to transfect a host which, in turn, is plated. Individual colonies are picked for sequencing.
- a preferred protocol for preparing tagged reference DNA for loading onto microparticles is described. Briefly, cDNA from each of the cell or tissue types of interest is prepared and directionally cloned into a vector containing the tag element of Formula I. Preferably, the mRNA extracted from such cells or tissues is combined, usually in equal proportions, prior to first strand synthesis. mRNA is obtained using standard protocols, after which first and second strand synthesis is carried out as exemplified and the resulting cDNAs are inserted into a vector containing a tag element of Formula I, or like tag element.
- the vectors containing the tag-cDNA conjugates are then used to transform a suitable host, typically a conventional bacterial host, after which a sample of cells from the host culture is further expanded and vector DNA is extracted.
- the tag-cDNA conjugates are preferably amplified from the vectors by PCR and processed as described below for loading onto microparticles derivatized with tag complements. After the non- covalently attached strand is melted off, the cDNA-containing microparticles are ready to accept competitively hybridized gene products in accordance with the invention. Specific guidance relating to the indicated steps is available in Sambrook et al. (cited above); Ausbel et al., editors, Current Protocols in Molecular Biology (John Wiley & Sons, New York, 1995); and like guides on molecular biology techniques.
- a pellet of approximately 5 ⁇ g of mRNA is resuspended in 45 ⁇ l (final volume) of a first strand pre-mix consisting of 10 ⁇ l 5x Superscript buffer (250 mM Tris-Cl, pH 8.3, 375 mM KC1, and 15 mM MgCl 2 ) (GIBCO BRL) (or like reverse transcriptase buffer), 5 ⁇ l 0.1 M dithiothreitol (DTT), 2.5 ⁇ l 3dNTP/methyl-dCTP mix (10 ⁇ M each of dATP, dGTP, dTTP, and 5-methyl-dCTP, e.g available from Pharmacia Biotech), 1 ⁇ l RNasin, 12 ⁇ l 0.25 ⁇ g/ ⁇ l of reverse transcription primer shown below, and 14.5 ⁇ l H2O. 5'-biotin-GACATGCTGCATTGAGACGATTCTTTTTTTTTTTTTTTTTTTTV
- V represents A, C, or G
- B represents C, G, or T.
- the reverse transcription primer sequence has been selected to give a Bsm BI site in the cDNAs which results in a 5'-GCAT overhang upon digestion with Bsm BI.
- the cDNA is resuspended in the manufacturer's recommended buffer for digestion with Dpn II (New England Biolabs, Beverely, MA), which is followed by capture of the biotinylated fragment on avidinated beads (Dynal, Oslo, Norway). After washing, the captured fragments are digested with Bsm BI to release the following cDNAs (SEQ ID NO: 4) which are precipitated in ethanol:
- a conventional cloning vector such as BlueScript II, pBC, or the like (Stratagene Cloning Systems, La Jolla, CA), is engineered to have the following sequence of elements (SEQ ID NO: 5)(which are those shown in Formula I):
- the vector After digestion with Bbs I and Bam HI, the vector is purified by gel electrophoresis and combined with the cDNAs for ligation. Note that the vector has been engineered so that the Bbs I digestion results in an end compatible with the Bsm Bl-digested end of the cDNAs. After ligation, a suitable host bacteria is transformed and a culture is expanded for subsequent use.
- the tag-cDNA conjugates are amplified out of the vectors by PCR using a conventional protocol, such as the following.
- a conventional protocol such as the following.
- the following reaction components are combined: 1 ⁇ l vector DNA (125 ng/ ⁇ l for a library, IO 9 copies for a single clone); 10 ⁇ l lOx Klentaq Buffer (Clontech).
- the PCR is run in an MJR DNA Engine (MJ Research), or like thermal cycler, with the following protocol: 1) 94°C for 4 min; 2) 94°C 30 sec; 3) 67°C 3 min; 4) 8 cycles of steps 2 and 3; 5) 94°C 30 sec, 6) 64°C 3 min, 7) 22 cycles of steps 5 and 6; 8) 67°C for 3 min; and 9) hold at 4°C.
- the 8 PCR mixtures are pooled and 700 ⁇ l phenol is added at room temperature, after which the combined mixture is vortexed for 20-30 sec and then centrifuged at high speed (e.g. 14,000 rpm in an Eppendorf bench top centrifuge, or like instrument) for 3 min.
- the supernatant is removed and combined with 700 ⁇ l chloroform (24:1 mixture of chloroform:iso-amyl alcohol) in a new tube, vortexed for 20-30 sec, and centrifuged for 1 min, after which the supernatant is transferred to a new tube and combined with 80 ⁇ l 3M sodium acetate and 580 ⁇ l isopropanol. After centrifuging for 20 min, the supernatant is removed and 1 ml 70% ethanol is added. The mixture is centrifuged for 5-10 min, after which the ethanol is removed and the precipitated DNA is dried in a speedvac. After resuspension, the cDNA is purified on avidinated magnetic beads
- GMA beads with tag complements are prepared by combinatorial synthesis on an automated DNA synthesizer (Gene Assembler Special 14 Primers,
- a 28-nucleotide "spacer" sequence is synthesized, followed by the tag complement sequence (8 "words” of 4 nucleotides each for a total of 32 nucleotides in the tag complement), and a sequence of three Cs.
- the beads are derivatized with a 63-mer oligonucleotide.
- the length of the "spacer" sequence is not critical; however, the proximity of the bead surface may affect the activity of enzymes that are use to treat tag complements or captured sequences.
- the spacer is between 10 and 30 nucleotides, inclusive.
- the following sequence (SEQ ID NO: 6), containing a Pac I site, is employed in the present embodiment:
- the tag-cDNA conjugates are hybridized to tag compliments on beads of a number corresponding to at least a full repertoire of tag complements, which in the case of the present embodiment is 8 8 , or about 1.6 x IO 7 beads.
- the number of beads in a given volume is readily estimated with a hemocytometer.
- the 5' ends of the tag complements are phosphorylated, preferably by treatment with a polynucleotide kinase. Briefly, 2.5 x 10 8 beads suspended in 100 ⁇ l H 2 O are combined with 100 ⁇ l lOx NEB buffer No.
- the tag-cDNA conjugates as prepared above are suspended in 50 ⁇ l H O and the resulting mixture is combined with 40 ⁇ l 2.5x hybridization buffer, after which the combined mixture is filtered through a Spin-X spin column (0.22 ⁇ m) using a conventional protocol to give a filtrate containing the tag-cDNA conjugates.
- lx hybridization buffer (10 mM NaPO4 (pH 7.2), 500 mM NaCl, 0.01% Tween 20, 3% dextran sulfate) is added and the mixture is vortexed to fully resuspend the beads, after which the mixture is centrifuged so that the beads form a pellet and the supernatant is removed.
- the tag-cDNA conjugates in the above filtrate are incubated at 75°C for 3 min and combined with the beads, after which the mixture is vortexed to fully resuspend the beads.
- the resulting mixture is further incubated at 75°C with vortexing for approximately three days (60 hours).
- the mixture is centrifuged for 2 min and the supernatant is removed, after which the beads are washed twice with 500 ⁇ l TE/Tween and resuspended in 500 ⁇ l lx NEB buffer No. 2 with .01% Tween 20.
- the beads are incubated at 64°C in this solution for 30 min, after which the mixture is centrifuged so that the beads form a pellet, the supernatant is removed, and the beads are resuspended in 500 ⁇ l TE/Tween.
- Loaded beads are sorted from unloaded beads using a high speed cell sorter, preferably a MoFlo flow cytometer equipped with an argon ion laser operating at 488 nm (Cytomation, Inc., Ft. Collins, CO), or like instrument.
- the loaded beads are subjected to a fill-in reaction by combining them with the following reaction components: 10 ⁇ l lOx NEB buffer No. 2, 0.4 ⁇ l 25 mM dNTPs, 1 ⁇ l 1% Tween 20, 2 ⁇ l T4 DNA polymerase (10 units/ml), and 86.6 ⁇ l H 2 O, for a final reaction volume of 100 ⁇ l.
- the reaction mixture After incubation at 12°C for 30 min with vortexing, the reaction mixture is centrifuged so that the beads form a pellet and the supernatant is removed.
- the pelleted beads are resuspended in a ligation buffer consisting of 15 ⁇ l lOx NEB buffer No. 2, 1.5 ⁇ l 1% Tween 20, 1.5 ⁇ l 100 mM ATP, 1 ⁇ l T4 DNA ligase (400 units/ ml), and 131 ⁇ l H 2 O, to give a final volume of 150 ⁇ l.
- the ligation reaction mixture is incubated at 37°C for 1 hr with vortexing, after which the beads are pelleted and washed once with lx phosphate buffered saline (PBS) with 1 mM
- the beads are resuspended in 45 ⁇ l PBS (with 1 mM CaCl 2 ) and combined with 6 ⁇ l Pronase solution (10 mg/ml, Boehringer Mannheim, Indianapolis, IN), after which the mixture is incubated at 37°C for 1 hr with vortexing. After centrifugation, the loaded beads are washed twice with TE/Tween and then once with lx NEB Dpn II buffer (New England Biolabs, Beverly, MA).
- the tag-cDNA conjugates loaded onto beads are cleaved with Dpn II to produce a four-nucleotide protmding strand to which a complementary adaptor carrying a 3 '-label is ligated. Accordingly, the loaded beads are added to a reaction mixture consisting of the following components: 10 ⁇ l lOx NEB Dpn II buffer, 1 ⁇ l 1% Tween, 4 ⁇ l Dpn II (50 units/ml), and 85 ⁇ l H 2 O, to give a final reaction volume of 100 ⁇ l.
- the mixture is incubated at 37°C overnight with vortexing, after which the beads are pelleted, the supernatant is removed, and the beads are washed once with lx NEB buffer No. 3.
- the protmding strands of the tag-cDNA conjugates are treated with a phosphatase, e.g. calf intestine phosphatase (CIP), to remove the 5' phosphates.
- CIP calf intestine phosphatase
- the loaded beads are added to a reaction mixture consisting of the following components: 10 ⁇ l lOx NEB buffer No.
- 3'-labeled adaptor (SEQ ID NO: 7) is prepared using conventional reagents, e.g. Clontech Laboratories (Palo Alto, CA):
- p is a 5' phosphate group and "FAM” is a fluorescein dye attached to the 3' carbon of the last nucleotide of the top strand by a commercially available 3' linker group (Clontech Laboratories).
- the ligation is carried out in the following reaction mixture: 5 ⁇ l lOx NEB buffer No. 2, 0.5 ⁇ l 1% Tween 20, 0.5 ⁇ l 100 mM ATP, 5 ml 3'-labeled adaptor (100 pmol/ ⁇ l), 2.5 ⁇ l T4 DNA ligase (400 units/ ⁇ l) and 36.5 ⁇ l H 2 O, to give a final reaction volume of 50 ⁇ l.
- the reaction mixture is incubated at 16°C overnight with vortexing, after which the beads are washed once with PBS containing 1 mM CaCl 2 and treated with Pronase as described above. After this initial ligation, the nick remaining between the adaptor and tag-cDNA conjugate is sealed by simultaneously treating with both a kinase and a ligase as follows. Loaded beads are resuspended in a reaction mixture consisting of the following components: 15 ⁇ Ox NEB buffer No.
- reaction mixture is incubated at 37°C for 1 hr with vortexing, after which the beads are washed once with PBS containing 1 mM CaCl 2 , treated with Pronase as described above, and washed twice with TE/Tween.
- the reference DNA on the beads is ready for competitive hybridization of differentially expressed gene products.
- Gal+ SUC2 CUPl are grown in separate rich and minimal media cultures essentially as describe by Wodicka et al. (cited above). mRNA extracted from cells grown under both conditions are used to establish a reference cDNA population which is tagged, sampled, amplified, labeled, and loaded onto microparticles. Loaded microparticles are isolated by FACS, labels are removed, and the non-covalently bound strands of the loaded DNA are melted off and removed.
- Yeast cells are grown at 30°C either in rich medium consisting of YPD (yeast extract peptone/glucose, Bufferad, Newark, NJ) or in minimal medium (yeast nitrogen base without amino acids, plus glucose, Bufferad). Cell density is measured by counting cells from duplicate dilutions, and the number of viable cells per milliliter is estimated by plating dilutions of the cultures on YPD agar immediately before collecting cells for mRNA extraction.
- YPD yeast extract peptone/glucose, Bufferad, Newark, NJ
- minimal medium yeast nitrogen base without amino acids, plus glucose, Bufferad
- RNA is extracted as follows for both the construction of the reference DNA library and for preparation of DNA for competitive hybridization.
- Total RNA is extracted from frozen cell pellets using a hot phenol method, described by Schmitt et al., Nucleic Acids Research, 18: 3091-3092 (1990), with the addition of a chloroform- isoamyl alcohol extraction just befor precipitation of the total RNA.
- Phase-Lock Gel (5 Prime-3 Prime, Inc., Boulder, CO) is used for all organic extractions to increase RNA recovery and decrease the potential for contamination of the RNA with material from the organic interface.
- Poly(A) + RNA is purified from the total RNA with an oligo-dT selection step (Oligotex, Qiagen, Chatsworth, CA).
- each of mRNA from cells grown on rich medium and minimal medium are mixed for construction of a cDNA library in a pUC19 containing the tag repertoire of Formula I.
- the tag repertoire of Formula I is digested with Eco RI and Bam HI and inserted into a similarly digested pUC19.
- the mRNA is reverse transcribed with a commercially available kit (Sfrategene, La Jolla, CA) using an olgio-dT primer containing a sequence which generates a Bsm BI site identical to that of Formula I upon second strand synthesis.
- the resulting cDNAs are cleaved with Bsm BI and Dpn II and inserted into the tag-containing pUC19 after digestion with Bsm BI and Bam HI. After transfection and colony formation, the density of pUC19 tranformants is determined so that a sample containing approximately thirty thousand tag-cDNA conjugates may be obtained and expanded in culture. Altematively, a sample of tag- cDNA conjugates are obtained by picking approximately 30 thousand clones, which are then mixed and expanded in culture.
- the tag-cDNA conjugates are amplified by PCR with 5-methyldeoxycytosine triphosphate substituted for deoxycytosine triphosphate.
- the following 19-mer forward and reverse primers (SEQ ID NO: 8 and SEQ ID NO: 9), specific for flanking sequences in pUC19, are used in the reaction:
- FAM is an NHS ester of fluorescein (Clontech Laboratories, Palo Alto, CA) coupled to the 5' end of the reverse primer via an amino linkage, e.g. Amino linker II (Perkin-Elmer, Applied Biosystems Division, Foster City, CA).
- the reverse primer is selected so that a Not I site is reconstituted in the double stranded product.
- the tag-cDNA conjugates are isolated on avidinated beads, e.g. M-280 Dynabeads (Dynal, Oslo, Norway).
- the cDNAs bound to the beads are digested with Pac I releasing the tag-cDNA conjugates and a stripping reaction is carried out to render the oligonucleotide tags single stranded.
- the tag-cDNA conjugate is purified by phenol-chloroform extraction and combined with 5.5 Om GMA beads carrying tag complements, each tag complement having a 5' phosphate.
- Hybridization is conducted under stringent conditions in the presence of a thermal stable ligase so that only tags forming perfectly matched duplexes with their complements are ligated.
- the GMA beads are washed and the loaded beads are concentrated by FACS sorting, using the fluorescently labeled cDNAs to identify loaded GMA beads.
- the isolated beads are treated with Pac I to remove the fluorescent label, after which the beads are heated in an NaOH solution using conventional protocols to remove the non-covalently bound strand. After several washes the GMA beads are ready for competitive hybridization.
- mRNA is extracted from cells of each culture and two populations of labeled polynucleotides are produced by a single round of poly(dT) primer extension by a reverse transcriptase in the presence of fluorescently label nucleoside triphosphates. Equal amounts of each of the labeled polynucleotides are then combined with the GMA beads of Example 1 carrying the reference DNA population for competitive hybridization, after which the beads are analyzed by FACS and those in the off-diagonal regions are accumulated for MPSS analysis.
- Cy3-dUTP or CY5-dUTP are inco ⁇ orated into cDNAs during reverse transcription of 1. ⁇ g of poly(A) + RNA obtained as described in Example 1 using a poly(dT) ⁇ 6 primer in separate reactions.
- the reaction mixture is transferred to ice and a premixed solution, consisting of 200 U Superscript II (Gibco), buffer, deoxyribonucleoside triphosphates, and fluorescent nucleoside triphosphates are added to give the following concentrations: 500 ⁇ M for dATP, dCTP, and dGTP; 200 ⁇ M for dTTP; and 100 mM each for Cy3-dUTP or CY5-dUTP.
- a premixed solution consisting of 200 U Superscript II (Gibco), buffer, deoxyribonucleoside triphosphates, and fluorescent nucleoside triphosphates are added to give the following concentrations: 500 ⁇ M for dATP, dCTP, and dGTP; 200 ⁇ M for dTTP; and 100 mM each for Cy3-dUTP or CY5-dUTP.
- the GMA beads After washing twice in 2 x SSC and 0.2% SDS, the GMA beads are resuspended in NEB-2 buffer (New England Biolabs, Beverly, MA) and loaded in a Coulter EPICS Elite ESP flow cytometer for analysis and sorting. In a two dimensional fluorescence intensity contour plot, the GMA beads generate a pattern as shown in Figure la. Sorting parameters are set as shown in Figure lb so that GMA beads in the off-diagonal regions (112) are sorted and collected for MPSS analysis. The labeled cDNA strands are melted from the GMA beads and removed by centrifugation.
- a primer is annealed to the primer binding site shown in Formula I and extended in a conventional polymerization reaction to reconstitute the double stranded DNAs on the GMA beads which include the Dpn II site, described above.
- beads loaded with tag-cDNA conjugates are placed in an instrument for MPSS analysis, as described in Albrecht et al. (cited above).
- the top strands of the following 16 sets of 64 encoded adaptors (SEQ ID NO:
- N is any of dA, dC, dG, or dT; p is a phosphate group; and the nucleotides indicated in lower case letters are the 12-mer oligonucleotide tags. Each tag differs from every other by 6 nucleotides. Equal molar quantities of each adaptor are combined in NEB #2 restriction buffer (New England Biolabs, Beverly, MA) to form a mixture at a concentration of 1000 pmol/ ⁇ L.
- Each of the 16 tag complements are separately synthesized as amino- derivatized oligonucleotides and are each labeled with a fluorescein molecule (using an NHS-ester of fluorescein, available from Molecular Probes, Eugene, OR) which is attached to the 5' end of the tag complement through a polyethylene glycol linker (Clonetech Laboratories, Palo Alto, CA).
- a fluorescein molecule using an NHS-ester of fluorescein, available from Molecular Probes, Eugene, OR
- the sequences of the tag complements are simply the 12-mer complements of the tags listed above.
- Ligation of the adaptors to the target polynucleotide is carried out in a mixture consisting of 5 ⁇ l beads (20 mg), 3 ⁇ L NEB lOx ligase buffer, 5 ⁇ L adaptor mix (25 nM), 2.5 ⁇ L NEB T4 DNA ligase (2000 units/ ⁇ L), and 14.5 ⁇ L distilled water.
- the mixture is incubated at 16°C for 30 minutes, after which the beads are washed 3 times in TE (pH 8.0).
- the 3' phosphates of the ligated adaptors are removed by treating the polynucleotide-bead mixture with calf intestinal alkaline phosphatase (CIP) (New England Biolabs, Beverly, MA), using the manufacturer's protocol. After removal of the 3' phosphates, the CIP may be inactivated by proteolytic digestion, e.g. using PronaseTM (available form Boeringer Mannhiem, Indianapolis, IN), or an equivalent protease, with the manufacturer's protocol.
- CIP calf intestinal alkaline phosphatase
- the polynucleotide-bead mixture is then washed, treated with a mixture of T4 polynucleotide kinase and T4 DNA ligase (New England Biolabs, Beverly, MA) to add a 5' phosphate at the gap between the target polynucleotide and the adaptor, and to complete the ligation of the adaptors to the target polynucleotide.
- T4 polynucleotide kinase and T4 DNA ligase New England Biolabs, Beverly, MA
- each of the labeled tag complements is applied to the polynucleotide-bead mixture under conditions which permit the formation of perfectly matched duplexes only between the oligonucleotide tags and their respective complements, after which the mixture is washed under stringent conditions, and the presence or absence of a fluorescent signal is measured.
- Tag complements are applied in a solution consisting of 25 nM tag complement 50 mM NaCl, 3 mM Mg, 10 mM Tris-HCl (pH 8.5), at 20°C, incubated for 10 minutes, then washed in the same solution (without tag complement) for 10 minute at 55°C.
- the encoded adaptors are cleaved from the polynucleotides with Bbv I using the manufacturer's protocol. After an initial ligation and identification, the cycle of ligation, identification, and cleavage is repeated three times to give the sequence of the 16 terminal nucleotides of the target polynucleotide.
- analysis of the hybridized encoded adaptors takes place in an instrument which i) constrains the loaded microparticles to be disposed in a planar array in a flow chamber, ii) permits the programmed delivery of process reagents to the flow chamber, and iii) detects simultaneously optical signals from the array of microparticles.
- an instrument which i) constrains the loaded microparticles to be disposed in a planar array in a flow chamber, ii) permits the programmed delivery of process reagents to the flow chamber, and iii) detects simultaneously optical signals from the array of microparticles.
- flow chamber (500) is prepared by etching a cavity having a fluid inlet (502) and outlet (504) in a glass plate (506) using standard micromachining techniques, e.g.
- the dimension of flow chamber (500) are such that loaded microparticles (508), e.g. GMA beads, may be disposed in cavity (510) in a closely packed planar monolayer of 100-200 thousand beads. Cavity (510) is made into a closed chamber with inlet and outlet by anodic bonding of a glass cover slip (512) onto the etched glass plate (506), e.g. Pomerantz, U.S. patent 3,397,279.
- loaded microparticles (508) e.g. GMA beads
- Cavity (510) is made into a closed chamber with inlet and outlet by anodic bonding of a glass cover slip (512) onto the etched glass plate (506), e.g. Pomerantz, U.S. patent 3,397,279.
- Reagents are metered into the flow chamber from syringe pumps (514 through 520) through valve block (522) controlled by a microprocessor as is commonly used on automated DNA and peptide synthesizers, e.g. Bridgham et al., U.S. patent 4,668,479; Hood et al., U.S. patent 4,252,769; Barstow et al., U.S. patent 5,203,368; Hunkapiller, U.S. patent 4,703,913; or the like.
- a microprocessor as is commonly used on automated DNA and peptide synthesizers, e.g. Bridgham et al., U.S. patent 4,668,479; Hood et al., U.S. patent 4,252,769; Barstow et al., U.S. patent 5,203,368; Hunkapiller, U.S. patent 4,703,913; or the like.
- Three cycles of ligation, identification, and cleavage are carried out in flow chamber (500) to give the sequences of 12 nucleotides at the termini of each of approximately 100,000 fragments.
- Nucleotides of the fragments are identified by hybridizing tag complements to the encoded adaptors as described above.
- Specifically hybridized tag complements are detected by exciting their fluorescent labels with illumination beam (524) from light source (526), which may be a laser, mercury arc lamp, or the like.
- Illumination beam (524) passes through filter (528) and excites the fluorescent labels on tag complements specifically hybridized to encoded adaptors in flow chamber (500).
- Resulting fluorescence (530) is collected by confocal microscope (532), passed through filter (534), and directed to CCD camera (536), which creates an electronic image of the bead array for processing and analysis by workstation (538).
- the cDNAs are treated with PronaseTM or like enzyme.
- Encoded adaptors and T4 DNA ligase (Promega, Madison, Wl) at about 0.75 units per ⁇ L are passed through the flow chamber at a flow rate of about 1-2 ⁇ L per minute for about 20-30 minutes at 16°C, after which 3' phosphates are removed from the adaptors and the cDNAs prepared for second strand ligation by passing a mixture of alkaline phosphatase (New England Bioscience, Beverly, MA) at 0.02 units per ⁇ L and T4 DNA kinase (New England Bioscience, Beverly, MA) at 7 units per ⁇ L through the flow chamber at 37°C with a flow rate of 1-2 ⁇ L per minute for 15-20 minutes.
- alkaline phosphatase New England Bioscience, Beverly, MA
- T4 DNA kinase New England Bioscience, Beverly, MA
- Tag complements at 25 nM concentration are passed through the flow chamber at a flow rate of 1-2 ⁇ L per minute for 10 minutes at 20°C, after which fluorescent labels carried by the tag complements are illuminated and fluorescence is collected.
- the tag complements are melted from the encoded adaptors by passing hybridization buffer through the flow chamber at a flow rate of 1-2 ⁇ L per minute at 55°C for 10 minutes.
- Encoded adaptors are cleaved from the cDNAs by passing Bbv I (New England Biosciences, Beverly, MA) at 1 unit/ ⁇ L at a flow rate of 1-2 ⁇ L per minute for 20 minutes at 37°C.
- the sensitivity of detecting different ratios of differently labeled cDNAs was tested by constmcting a reference DNA population consisting of a single clone and then competitively hybridizing to the reference DNA population different ratios of complementary strands labeled with different fluorescent dyes.
- the reference DNA population consisted of a cDNA clone, designated "88.11,” which is an 87-basepair fragment of an expressed gene of the human monocyte cell line THP- 1, available from the American Type Culture Collection (Rockville, Maryland) under accession number TIB 202.
- the nucleotide sequence of 88.11 has a high degree of homology to many entries in the GenBank Expressed Sequence Tag library, e.g.
- the reference DNA population which consisted of only 88.11 cDNA, was prepared as described in Example 1, with the exception that a special population of microparticles was prepared in which all microparticles had the same tag complement attached. The corresponding oligonucleotide tag was attached to the 88.11 cDNA. Thus, only monospecific populations of tags and tag complements were involved in the experiment. After competitive hybridization, the loaded microparticles were analyzed on a Cytomation, Inc. (Ft. Collins, CO) FACS instrument as described above.
- 88.11 cDNA was also cloned into a vector identical to that of Example 1 (330 of Figure 3b), except that it did not contain tag 336.
- 10 ⁇ g of vector DNA was linearized by cleaving to completion with Sau 3 A, an isoschizomer of Dpn II (342 of Figure 3b), after which two 1 ⁇ g aliquots of the purified linear DNA were taken. From each 1 ⁇ g aliquot, about 20 ⁇ g of labeled single stranded DNA product was produced by repeated cycles of linear amplification using primers specific for primer binding site 332.
- product was labeled by inco ⁇ oration of rhodamine RI 10-labeled dUTP (PE Applied Biosystems, Foster City, CA); and in the other aliquot, product was labeled by inco ⁇ oration of CY5 -labeled dUTP (Amersham Co ⁇ oration, Arlington Heights, IL). Quantities of the labeled products were combined to form seven 5 ⁇ g amounts of the two products in ratios of 1:1, 2:1, 1:2, 4:1, 1:4, 8:1, and 1:8.
- the 5 ⁇ g quantities of labeled product were separately hybridized to 1.6 x 10 5 microparticles (GMA beads with 88.11 cDNA attached) overnight at 65°C in 50 ⁇ l 4x SSC with 0.2% SDS, after which the reaction was quenched by diluting to 10 ml with ice-cold TE/Tween buffer (defined above).
- the loaded microparticles were centrifuged, washed by suspending in 0.5 ml lx SSC with 0.2% SDS for 15 min at 65°C, centrifuged, and washed again by suspending in 0.5 ml 0. lx SSC with 0.2% SDS for 15 min at 55°C. After the second washing, the microparticles were centrifuged and resuspended in 0.5 ml TE/Tween solution for FACS analysis.
- Figures 5a-5e The results are shown in Figures 5a-5e, where in each Figure the vertical axis corresponds to CY5 fluorescence and the horizontal axis corresponds to rhodamine RI 10 fluorescence.
- Figure 5 a a population of microparticles were combined that had either all RI 10-labeled DNA or all CY5-labeled DNA hybridized to the complementary reference strands. Contours 550 and 552 are clearly distinguished by the detection system of the FACS instrument and microparticles of both populations produce readily detectable signals.
- Figure 5b illustrates the case where the RI 10- and CY5-labeled strands are hybridized in equal proportions. As expected, the resulting contour is located on the diagonal of the graph and corresponds to the position expected for non-regulated genes.
- Figures 5c through 5e show the analysis of three pairs of competitive hybridizations: i) RI 10- and CY5-labeled strands hybridized in a 2:1 concentration ratio and a 1 :2 concentration ratio, ii) RI 10- and CY5-labeled strands hybridized in a 4:1 concentration ratio and a 1 :4 concentration ratio, and iii) R110- and CY5-labeled strands hybridized in an 8:1 concentration ratio and a 1:8 concentration ratio.
- the data of Figure 5c suggest that genes up-regulated or down- regulated by a factor of two are detectable in the present embodiment, but that significant overlap may exist between signals generated by regulated and non- regulated genes.
- Figures 5d and 5e suggest that genes up-regulated or down-regulated by a factor of four or higher are readily detectable over non-regulated genes.
- a reference DNA population attached to microparticles was constructed from cDNA derived from THP-1 cells stimulated as indicated below. Equal concentrations of labeled cDNAs from both stimulated and unstimulated THP-1 cells were then competitively hybridized to the reference DNA population, as described in Example 1, and the microparticles carrying the labeled cDNAs were analyzed by a FACS instrument.
- THP-1 cells were stimulated by treatment with phorbol 12-myristate 13-acetate (PMA) and lipopolysaccharide (LPS). THP-1 cells were grown in T-165 flasks (Costar, No. 3151) containing 50 ml
- DMEM/F12 media (Gibco, No. 11320-033) supplemented with 10% fetal bovine serum (FBS)(Gibco, No. 26140-038), 100 units/ml penicillin, 100 ⁇ g/ml streptomycin (Gibco, No. 15140-122), and 0.5 ⁇ M ⁇ -mercaptoethanol (Sigma, No. M3148). Cultures were seeded with 1 x 10 5 cells/ml and grown to a maximal density of 1 x 10°. Doubling time of the cell populations in culture was about 36 hours.
- Cells were treated with PMA as follows: Cells from a flask (about 5 x IO 7 cells) were centrifuged (Beckman model GS-6R) at 1200 ⁇ m for 5 minutes and resuspended in 50 ml of fresh culture media (without antibiotics) containing 5 ⁇ l of 1.0 mM PMA (Sigma, No. P-8139) in DMSO (Gibco No. 21985-023) or 5 ⁇ l DMSO (for the unstimulated population), after which the cells were cultured for 48 hours. Following the 48 hour incubation, media and non-adherent cells were aspirated from the experimental flask (i.e.
- Both the cultures of stimulated and unstimulated cells were incubated at 37°C for four hours, after which cells were harvested as follows: Media was aspirated from the cultures and adherent cells were washed twice with warm PBS, after which 10 ml PBS was added and the cells were dislodged with a cell scaper. The dislodged cells were collected and their concentration was determined with a hemocytometer, after which they were centrifuged (Beckman model GS-6R) at 1200 ⁇ m for 5 minutes to form a pellet which was used immediately for RNA extraction. mRNA was extracted from about 5 x IO 6 cells using a FastTrack 2.0 kit (No. Kl 593-02, Invitrogen, Inc.
- Example 4 Following the protocol of Example 4, approximately 2.5 ⁇ g of rhodamine RI 10-labeled single stranded DNA was produced from the cDNA library derived from stimulated cells, and approximately 2.5 ⁇ g of CY5 -labeled single stranded DNA was produced from the cDNA library derived from unstimulated cells. The two 2.5 ⁇ g aliquots were mixed and competitively hybridized to the reference DNA on 9.34 x IO 5 microparticles. The reaction conditions and protocol was as described in Example 4. After hybridization, the microparticles were sorted by a Cytomation, Inc.
- FIG. 6 contains a conventional FACS contour plot 600 of the frequencies of microparticles with different fluorescent intensity values for the two fluorescent dyes. Approximately 10,000 microparticles corresponding to up-regulated genes (sort window 602 of Figure 6) were isolated, and approximately 12,000 microparticles corresponding to down-regulated genes (sort window 604 of Figure 6) were isolated. After melting off the labeled strands, as described above, the cDNAs carried by the microparticles were amplified using a commercial PCR cloning kit (Clontech Laboratories, Palo Alto, CA), and cloned into the manufacturer's recommended cloning vector.
- a commercial PCR cloning kit (Clontech Laboratories, Palo Alto, CA), and cloned into the manufacturer's recommended cloning vector.
- a reference DNA population attached to microparticles was constmcted from cDNA derived from stimulated THP-1 cells. cDNA from stimulated and unstimulated
- THP-1 cells was prepared for competitive hybridization as follows. 20 ⁇ g each of the
- THP-1 unstimulated probe library U3A-TL
- THP-1 stimulated probe library S3 A-TL
- the DNA was purified by phenol/chloroform extraction and fluorescently labelled by PCR.
- CY5 and RI 10 were used to label each condition.
- the U3 A-TL DNA was labeled with CY5 and the S3 A-TL DNA was labeled with RI 10.
- a reaction mixture containing 80 ⁇ l 1 OX PCR Buffer; 16 ⁇ l biotinylated primer (B-Primer, 125 pmole/:l); 16 ⁇ l dNTPs (6.25 mM); 4 ⁇ g template; 16 ⁇ l Klentaq enzyme; 64 ⁇ l RI 10 dUTP or 6.4 ⁇ l of CY5 dUTP; and water to bring the total volume to 800 ⁇ l.
- the Comp 11 bead library consisted of 2,667,369 beads, with a complexity of 1 million clones from the THP-1 stimulated library.
- the beads were prepared as described above as outlined in Figure 3.
- the starting PMT2 mean for the FITC signal was 19.5.
- the duplexed DNA on the beads was denatured with 2.5 ml 150mM NaOH washes at RT for 15min with mild vortexing.
- the efficiency of the denaturization was determined by measuring the remaining FITC signal mean, which was 2.2, i.e., 11.3% residual fluorescence.
- the beads were washed twice in .5 ml of 4X SSC .1% SDS.
- the recovered samples were rinsed 2 times with IX SSC /.1% SDS, resuspended in .5 ml of IX SSC /.1%SDS, and washed at 65°C for 15 min.
- the beads were rinsed in .IX SSC /.1%SDS and washed at 55°C in .IX SSC 1.1% SDS for 15 min.
- the samples were rinsed with TE Tween and 10,000 events of both samples were analyzed on the BD FacsCaliber. 10,163 beads (1.15%), the brightest CY5 off the 1:1 diagonal, were sorted. 11,977 beads (1.35%), the brightest RI 10 off the 1:1 diagonal, were sorted.
- the beads were pooled in a PCR reaction, TA cloned, and sequenced. The identified sequences are listed in Tables 3 and 4.
- Example 6 cDNA from stimulated and unstimulated THP-1 cells was prepared for competitive hybridization as described in Example 6.
- the reference DNA population was prepared as described in Example 6, except that the Comp 15 bead library consisted of 2,570,000 beads, with a complexity of 1 million clones from the THP-1 stimulated library and the THP-1 unstimulated library (50% of each). 13,988 beads (.87%), the brightest CY5 off the 1:1 diagonal, were sorted. 17,393 beads (1.08%), the brightest RI 10 off the 1:1 diagonal, were sorted.
- the identified sequences are listed in Tables 7 and 8.
- rare genes are isolated from stimulated THP-1 cells by collecting beads of lower relative intensity. Bead and probe libraries were constmcted from mRNA prepared from phorbol ester treated THP-1 cultured cells.
- a total of 1,260,000 beads were sorted.
- the beads were filled in and ligated.
- the top strand of the beads was stripped with 2.5 ml 150 mM NaOH washes at room temperature for 15 minutes with mild vortexing.
- the beads were washed twice in 0.5 ml of 4X SSC/0.1% SDS.
- 100,000 beads were hybridized overnight with 50 ng of CY5 labelled probe from stimulated THP-1 cells in 4X SSC/0.1% SDS at 65°.
- the recovered samples were rinsed 2 times with IX SSC/0.1% SDS, resuspended in 0.5 ml of IX SSC/0.1% SDS, and washed at 65°C for 15 minutes.
- Bead and probe libraries were constmcted from commercially available mRNA from bone marrow.
- Six bead libraries 160K complexity) were loaded twice to BP 12 combitagged beads. They formed mixes 216, 217, 218, and 219. A total of 3,150,000 beads were sorted. The beads were filled in and ligated. The top strand of mix 217 was stripped off with NaOH.
- the CT1 bone marrow probe was linearly amplified with CY5 nucleotides and then purified. 200,000 beads were hybridized with 5 and 50 ng of probe overnight at 65°. 180,000 clones from the 5 nG hybridization were interrogated and sorted. Sample CT001 contained 996 clones which barely hybridized any CY5 probe. CT002 sample contained 1988 clones that did not find enough probe to migrate to the diagonal. These beads contained the least frequent copies in our probe library. 200 clones from each gate (see Figure 8) were picked for sequence analysis.
- Bead and probe libraries were constmcted from mRNA prepared from muscle tissue in two states: glucose normal (basal) and glucose starved (clamp).
- Six bead libraries 160K complexity) from the glucose normal state were loaded to BP 12 combitagged beads to form mix 237. A total of 810,000 beads were sorted. The beads were filled in and ligated. The beads were digested with DpnII enzyme and ligated to an adapter with FITC on the strand opposite to the covalently attached DNA strand. The top strand of mix 217 was stripped off with NaOH.
- the CT1 glucose normal probe 13,510,000 complexity was linearly amplified with CY5 nucleotides and then purified.
- the CT2 glucose starred probe (7,132,000 complexity) was linearly amplified with R110 nucleotides and then purified. 250,000 beads were hybridized with 5ug of each probe overnight at 65°. 230,000 clones were interrogated and sorted. Sample UPOOl contained 968 clones which were upregulated. Sample DNOOl contained 1652 clones which were down regulated. 1000 clones from each gate (see Figure 9) were picked for sequence analysis. The identified sequences are listed in Tables 10 and 11.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99901448A EP1054999B1 (en) | 1998-01-09 | 1999-01-08 | Solid phase selection of differentially expressed genes |
JP2000527674A JP4344086B2 (en) | 1998-01-09 | 1999-01-08 | Solid phase selection of differentially expressed genes |
HU0100242A HUP0100242A3 (en) | 1998-01-09 | 1999-01-08 | Solid phase selection of differentially expressed genes |
CA002317695A CA2317695A1 (en) | 1998-01-09 | 1999-01-08 | Solid phase selection of differentially expressed genes |
AU21139/99A AU754929B2 (en) | 1998-01-09 | 1999-01-08 | Solid phase selection of differentially expressed genes |
DE69930729T DE69930729D1 (en) | 1998-01-09 | 1999-01-08 | SELECTION OF DIFFERENTIALLY EXPRESSED GENES AT THE FESTPHASE |
NO20003531A NO20003531L (en) | 1998-01-09 | 2000-07-07 | Fixed phase selection of differentially expressed genes |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US522298A | 1998-01-09 | 1998-01-09 | |
US09/005,222 | 1998-01-09 | ||
US09/130,446 | 1998-08-06 | ||
US09/130,546 US6265163B1 (en) | 1998-01-09 | 1998-08-06 | Solid phase selection of differentially expressed genes |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999035293A2 true WO1999035293A2 (en) | 1999-07-15 |
WO1999035293A3 WO1999035293A3 (en) | 1999-09-30 |
Family
ID=26674091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/000666 WO1999035293A2 (en) | 1998-01-09 | 1999-01-08 | Solid phase selection of differentially expressed genes |
Country Status (10)
Country | Link |
---|---|
US (2) | US6265163B1 (en) |
EP (1) | EP1054999B1 (en) |
KR (1) | KR100433782B1 (en) |
AT (1) | ATE322556T1 (en) |
AU (1) | AU754929B2 (en) |
CA (1) | CA2317695A1 (en) |
DE (1) | DE69930729D1 (en) |
NO (1) | NO20003531L (en) |
PL (1) | PL342114A1 (en) |
WO (1) | WO1999035293A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000055363A2 (en) * | 1999-03-12 | 2000-09-21 | Amersham Pharmacia Biotech Uk Ltd | Analysis of differential gene expression |
WO2001005808A2 (en) * | 1999-07-20 | 2001-01-25 | Affibody Technology Sweden Ab | In vitro selection and optional identification of polypeptides using solid support carriers |
EP1191107A2 (en) * | 2000-09-25 | 2002-03-27 | Schering Aktiengesellschaft | Method for the in vitro diagnosis of endometriosis |
WO2002027029A2 (en) * | 2000-09-27 | 2002-04-04 | Lynx Therapeutics, Inc. | Method for determining relative abundance of nucleic acid sequences |
EP1200820A2 (en) * | 1999-07-16 | 2002-05-02 | Rosetta Inpharmatics Inc. | Iterative probe design and detailed expression profiling with flexible in-situ synthesis arrays |
US6458530B1 (en) | 1996-04-04 | 2002-10-01 | Affymetrix Inc. | Selecting tag nucleic acids |
WO2002084283A2 (en) * | 2001-04-10 | 2002-10-24 | Nmi Naturwissenschaftliches Und Medizinisches Institut An Der Universität Tübingen In Reutlingen Stiftung Bürgerlichen Rechts | Method for determining analyte molecules in a sample |
EP1425290A1 (en) * | 2001-08-14 | 2004-06-09 | Mount Sinai School of Medicine | Use of intrinsic reporters of cell signaling for high content durg profiling and toxicity screening |
US6780594B2 (en) | 2000-09-25 | 2004-08-24 | Schering Aktiengesellschaft | Method for in vitro diagnosis of endometriosis |
EP1786924A1 (en) * | 2004-07-06 | 2007-05-23 | Genera Biosystems Pty Ltd | Method of detecting aneuploidy |
WO2009114185A2 (en) | 2008-03-12 | 2009-09-17 | The Rockefeller University | Methods and compositions for translational profiling and molecular phenotyping |
US7635566B2 (en) * | 2007-06-29 | 2009-12-22 | Population Genetics Technologies Ltd. | Methods and compositions for isolating nucleic acid sequence variants |
DE102021134368A1 (en) | 2021-12-22 | 2023-06-22 | Hochschule Reutlingen Körperschaft des öffentlichen Rechts | Device and method for detecting marked tumor cells of a tissue in a flowing liquid |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE43097E1 (en) | 1994-10-13 | 2012-01-10 | Illumina, Inc. | Massively parallel signature sequencing by ligation of encoded adaptors |
US6654505B2 (en) * | 1994-10-13 | 2003-11-25 | Lynx Therapeutics, Inc. | System and apparatus for sequential processing of analytes |
US6406848B1 (en) | 1997-05-23 | 2002-06-18 | Lynx Therapeutics, Inc. | Planar arrays of microparticle-bound polynucleotides |
US6743578B1 (en) * | 1998-12-18 | 2004-06-01 | The Regents Of The University Of California | Method for the detection of specific nucleic acid sequences by polymerase nucleotide incorporation |
US6815163B1 (en) * | 1998-12-23 | 2004-11-09 | Rutgers, The State University | Methods and kits for screening nucleic acid duplex stability |
US7468250B2 (en) * | 1998-12-23 | 2008-12-23 | Rutgers, The State University Of New Jersey | Methods and kits for screening nucleic acid duplex stability |
JP2003510017A (en) * | 1999-06-22 | 2003-03-18 | インビトロジェン コーポレイション | Improved primers and methods for nucleic acid detection and identification |
US6834122B2 (en) * | 2000-01-22 | 2004-12-21 | Kairos Scientific, Inc. | Visualization and processing of multidimensional data using prefiltering and sorting criteria |
US20030165859A1 (en) | 2001-10-23 | 2003-09-04 | Invitrogen Corporation | Primers and methods for the detection and discrimination of nucleic acids |
US20030166026A1 (en) * | 2002-01-09 | 2003-09-04 | Lynx Therapeutics, Inc. | Identification of specific biomarkers for breast cancer cells |
US20030170700A1 (en) * | 2002-01-09 | 2003-09-11 | Lynx Therapeutics, Inc. | Secreted and cell surface polypeptides affected by cholesterol and uses thereof |
EP1523554A2 (en) * | 2002-06-12 | 2005-04-20 | Riken | Method of utilizing the 5' end of transcribed nucleic acid regions for cloning and analysis |
WO2004001074A1 (en) * | 2002-06-21 | 2003-12-31 | Lynx Therapeutics, Inc. | Method for detecting foreign dna in a host genome |
GB0218087D0 (en) * | 2002-08-03 | 2002-09-11 | Epistem Ltd | Analysis of biological samples |
GB0218080D0 (en) * | 2002-08-03 | 2002-09-11 | Epistem Ltd | Analysis of biological samples |
EP1582599A1 (en) * | 2004-03-31 | 2005-10-05 | Takara Bio Inc. | Method for purifying microbeads |
US7867703B2 (en) * | 2004-08-26 | 2011-01-11 | Agilent Technologies, Inc. | Element defined sequence complexity reduction |
EP3543357A1 (en) | 2007-05-08 | 2019-09-25 | Trustees of Boston University | Chemical functionalization of solid-state nanopores and nanopore arrays and applications thereof |
US20100129810A1 (en) * | 2008-09-05 | 2010-05-27 | Life Technologies Corporation | Methods and systems for nucleic acid sequencing validation, calibration and normalization |
WO2010117620A2 (en) | 2009-03-30 | 2010-10-14 | Illumina, Inc. | Gene expression analysis in single cells |
CA2808576A1 (en) | 2009-09-30 | 2011-04-07 | Quantapore, Inc. | Ultrafast sequencing of biological polymers using a labeled nanopore |
US8835358B2 (en) | 2009-12-15 | 2014-09-16 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse labels |
WO2011103467A2 (en) | 2010-02-19 | 2011-08-25 | Life Technologies Corporation | Methods and systems for nucleic acid sequencing validation, calibration and normalization |
CA2865575C (en) | 2012-02-27 | 2024-01-16 | Cellular Research, Inc. | Compositions and kits for molecular counting |
US9651539B2 (en) | 2012-10-28 | 2017-05-16 | Quantapore, Inc. | Reducing background fluorescence in MEMS materials by low energy ion beam treatment |
US9862997B2 (en) | 2013-05-24 | 2018-01-09 | Quantapore, Inc. | Nanopore-based nucleic acid analysis with mixed FRET detection |
SG10201806890VA (en) | 2013-08-28 | 2018-09-27 | Cellular Res Inc | Massively parallel single cell analysis |
ES2789000T3 (en) | 2014-10-10 | 2020-10-23 | Quantapore Inc | Nanopore-based polynucleotide analysis with mutually inactivating fluorescent labels |
JP6757316B2 (en) | 2014-10-24 | 2020-09-16 | クアンタポール, インコーポレイテッド | Efficient optical analysis of polymers using nanostructured arrays |
EP3259371B1 (en) | 2015-02-19 | 2020-09-02 | Becton, Dickinson and Company | High-throughput single-cell analysis combining proteomic and genomic information |
EP3262192B1 (en) | 2015-02-27 | 2020-09-16 | Becton, Dickinson and Company | Spatially addressable molecular barcoding |
EP3835431B1 (en) | 2015-03-30 | 2022-11-02 | Becton, Dickinson and Company | Methods for combinatorial barcoding |
WO2016172373A1 (en) | 2015-04-23 | 2016-10-27 | Cellular Research, Inc. | Methods and compositions for whole transcriptome amplification |
WO2016196229A1 (en) | 2015-06-01 | 2016-12-08 | Cellular Research, Inc. | Methods for rna quantification |
KR102395450B1 (en) | 2015-09-11 | 2022-05-09 | 셀룰러 리서치, 인크. | Methods and Compositions for Normalizing Nucleic Acid Libraries |
EA037304B1 (en) | 2016-01-27 | 2021-03-09 | КАБУСИКИ КАЙСЯ ДиЭнЭйФОРМ | Method for decoding base sequence of nucleic acid corresponding to end region of rna and method for analyzing dna element |
JP7129343B2 (en) | 2016-05-02 | 2022-09-01 | ベクトン・ディキンソン・アンド・カンパニー | Accurate molecular barcoding |
US10301677B2 (en) | 2016-05-25 | 2019-05-28 | Cellular Research, Inc. | Normalization of nucleic acid libraries |
JP7046007B2 (en) | 2016-05-26 | 2022-04-01 | ベクトン・ディキンソン・アンド・カンパニー | How to adjust the molecular label count |
US10202641B2 (en) | 2016-05-31 | 2019-02-12 | Cellular Research, Inc. | Error correction in amplification of samples |
US10640763B2 (en) | 2016-05-31 | 2020-05-05 | Cellular Research, Inc. | Molecular indexing of internal sequences |
KR101879329B1 (en) * | 2016-06-13 | 2018-07-17 | 충북대학교 산학협력단 | RNA-seq expression data simulation method for differential gene expression analysis, and recording medium thereof |
EP3482196B1 (en) | 2016-07-05 | 2022-02-23 | Quantapore, Inc. | Optically based nanopore sequencing |
AU2017331459B2 (en) | 2016-09-26 | 2023-04-13 | Becton, Dickinson And Company | Measurement of protein expression using reagents with barcoded oligonucleotide sequences |
EP3568234B1 (en) | 2017-01-13 | 2023-09-06 | Cellular Research, Inc. | Hydrophilic coating of fluidic channels |
US11319583B2 (en) | 2017-02-01 | 2022-05-03 | Becton, Dickinson And Company | Selective amplification using blocking oligonucleotides |
KR20220124280A (en) | 2017-06-05 | 2022-09-13 | 백톤 디킨슨 앤드 컴퍼니 | Sample indexing for single cells |
ES2945191T3 (en) | 2018-05-03 | 2023-06-29 | Becton Dickinson Co | High-throughput multi-omics sample analysis |
US11365409B2 (en) | 2018-05-03 | 2022-06-21 | Becton, Dickinson And Company | Molecular barcoding on opposite transcript ends |
JP2022511398A (en) | 2018-10-01 | 2022-01-31 | ベクトン・ディキンソン・アンド・カンパニー | Determining the 5'transcription sequence |
EP3894552A1 (en) | 2018-12-13 | 2021-10-20 | Becton, Dickinson and Company | Selective extension in single cell whole transcriptome analysis |
WO2020150356A1 (en) | 2019-01-16 | 2020-07-23 | Becton, Dickinson And Company | Polymerase chain reaction normalization through primer titration |
EP4242322A3 (en) | 2019-01-23 | 2023-09-20 | Becton, Dickinson and Company | Oligonucleotides associated with antibodies |
WO2021092386A1 (en) | 2019-11-08 | 2021-05-14 | Becton Dickinson And Company | Using random priming to obtain full-length v(d)j information for immune repertoire sequencing |
US11649497B2 (en) | 2020-01-13 | 2023-05-16 | Becton, Dickinson And Company | Methods and compositions for quantitation of proteins and RNA |
WO2021231779A1 (en) | 2020-05-14 | 2021-11-18 | Becton, Dickinson And Company | Primers for immune repertoire profiling |
US11739443B2 (en) | 2020-11-20 | 2023-08-29 | Becton, Dickinson And Company | Profiling of highly expressed and lowly expressed proteins |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996012039A1 (en) * | 1994-10-13 | 1996-04-25 | Lynx Therapeutics, Inc. | Massively parallel sequencing of sorted polynucleotides |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE793185A (en) | 1971-12-23 | 1973-04-16 | Atomic Energy Commission | APPARATUS FOR QUICKLY ANALYZING AND SORTING PARTICLES SUCH AS BIOLOGICAL CELLS |
US4354114A (en) | 1979-10-09 | 1982-10-12 | Karnaukhov Valery N | Apparatus for investigation of fluorescence characteristics of microscopic objects |
US4812394A (en) | 1983-10-18 | 1989-03-14 | University Of California | Flow cytomeric measurement of DNA and incorporated nucleoside analogs |
US5206143A (en) | 1985-11-01 | 1993-04-27 | Smithkline Beecham Corporation | Method and reagents for performing subset analysis using quantitative differences in fluorescence intensity |
CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
US5721098A (en) | 1986-01-16 | 1998-02-24 | The Regents Of The University Of California | Comparative genomic hybridization |
US4791355A (en) | 1986-10-21 | 1988-12-13 | Coulter Electronics Inc. | Particle analyzer for measuring the resistance and reactance of a particle |
SE458968B (en) | 1987-06-16 | 1989-05-22 | Wallac Oy | BIOSPECIFIC ANALYTICAL PROCEDURE FOR MULTIPLE ANALYTICS WHICH DO NOT INCLUDE PARTICULAR COATING AND LABELING WITH FLUORESCING LABEL SUBSTANCES |
US4921805A (en) | 1987-07-29 | 1990-05-01 | Life Technologies, Inc. | Nucleic acid capture method |
US4942124A (en) | 1987-08-11 | 1990-07-17 | President And Fellows Of Harvard College | Multiplex sequencing |
US5104791A (en) | 1988-02-09 | 1992-04-14 | E. I. Du Pont De Nemours And Company | Particle counting nucleic acid hybridization assays |
GB8827160D0 (en) | 1988-11-21 | 1988-12-29 | Apothekernes Lab | Detection & quantitative determination of rna & dna |
US5237016A (en) | 1989-01-05 | 1993-08-17 | Siska Diagnostics, Inc. | End-attachment of oligonucleotides to polyacrylamide solid supports for capture and detection of nucleic acids |
EP0392546A3 (en) | 1989-04-14 | 1991-09-11 | Ro Institut Za Molekularnu Genetiku I Geneticko Inzenjerstvo | Process for determination of a complete or a partial contents of very short sequences in the samples of nucleic acids connected to the discrete particles of microscopic size by hybridization with oligonucleotide probes |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5173260A (en) | 1990-09-17 | 1992-12-22 | Eastman Kodak Company | Beads fused to a test device support |
EP0594763B1 (en) | 1991-07-16 | 1998-09-23 | Transmed Biotech Incorporated | Methods and compositions for simultaneous analysis of multiple analytes |
ATE148889T1 (en) | 1991-09-18 | 1997-02-15 | Affymax Tech Nv | METHOD FOR SYNTHESIS OF VARIOUS COLLECTIONS OF OLIGOMERS |
WO1993015228A1 (en) | 1992-01-29 | 1993-08-05 | Hitachi Chemical Co., Ltd. | Polynucleotide immobilized support |
AU3728093A (en) | 1992-02-19 | 1993-09-13 | Public Health Research Institute Of The City Of New York, Inc., The | Novel oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids |
FR2688283B1 (en) | 1992-03-04 | 1997-05-30 | Snecma | DEVICE FOR SEALING BETWEEN A PRESSURIZED VOLUME AND A LUBRICATED VOLUME. |
AU4329093A (en) | 1992-07-02 | 1994-01-31 | Erkki Soini | Biospecific multiparameter assay method |
US5629147A (en) * | 1992-07-17 | 1997-05-13 | Aprogenex, Inc. | Enriching and identifying fetal cells in maternal blood for in situ hybridization |
GB9315847D0 (en) * | 1993-07-30 | 1993-09-15 | Isis Innovation | Tag reagent and assay method |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
DE69535428T2 (en) | 1994-02-14 | 2007-12-06 | Smithkline Beecham Corp. | Method for finding differentially expressed genes |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5604097A (en) | 1994-10-13 | 1997-02-18 | Spectragen, Inc. | Methods for sorting polynucleotides using oligonucleotide tags |
US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
HUP9900910A2 (en) | 1995-06-07 | 1999-07-28 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
US5736330A (en) | 1995-10-11 | 1998-04-07 | Luminex Corporation | Method and compositions for flow cytometric determination of DNA sequences |
US5981180A (en) | 1995-10-11 | 1999-11-09 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and methods |
US5736332A (en) | 1995-11-30 | 1998-04-07 | Mandecki; Wlodek | Method of determining the sequence of nucleic acids employing solid-phase particles carrying transponders |
US5658736A (en) | 1996-01-16 | 1997-08-19 | Genetics Institute, Inc. | Oligonucleotide population preparation |
US6458530B1 (en) | 1996-04-04 | 2002-10-01 | Affymetrix Inc. | Selecting tag nucleic acids |
ATE356221T1 (en) | 1996-06-06 | 2007-03-15 | Solexa Inc | SEQUENCING BY LIGATION OF ENCODED ADAPTERS |
US6060240A (en) | 1996-12-13 | 2000-05-09 | Arcaris, Inc. | Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom |
US6013449A (en) | 1997-11-26 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Probe-based analysis of heterozygous mutations using two-color labelling |
-
1998
- 1998-08-06 US US09/130,546 patent/US6265163B1/en not_active Expired - Lifetime
-
1999
- 1999-01-08 AT AT99901448T patent/ATE322556T1/en not_active IP Right Cessation
- 1999-01-08 CA CA002317695A patent/CA2317695A1/en not_active Abandoned
- 1999-01-08 US US09/227,694 patent/US6511802B1/en not_active Expired - Lifetime
- 1999-01-08 DE DE69930729T patent/DE69930729D1/en not_active Expired - Lifetime
- 1999-01-08 EP EP99901448A patent/EP1054999B1/en not_active Expired - Lifetime
- 1999-01-08 KR KR10-2000-7007585A patent/KR100433782B1/en not_active IP Right Cessation
- 1999-01-08 AU AU21139/99A patent/AU754929B2/en not_active Ceased
- 1999-01-08 WO PCT/US1999/000666 patent/WO1999035293A2/en active IP Right Grant
- 1999-01-08 PL PL99342114A patent/PL342114A1/en unknown
-
2000
- 2000-07-07 NO NO20003531A patent/NO20003531L/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996012039A1 (en) * | 1994-10-13 | 1996-04-25 | Lynx Therapeutics, Inc. | Massively parallel sequencing of sorted polynucleotides |
Non-Patent Citations (3)
Title |
---|
DERISI J.L. ET AL.,: "Exploring the metabolic and genetic control of gene expression on a genomic scale" SCIENCE, vol. 278, - 24 October 1997 (1997-10-24) pages 680-686, XP002110854 * |
SCHENA M ET AL: "QUANTITATIVE MONITORING OF GENE EXPRESSION PATTERNS WITH A COMPLEMENTARY DNA MICROARRAY" SCIENCE, vol. 270, no. 5235, 20 October 1995 (1995-10-20), pages 467-470, XP000644675 ISSN: 0036-8075 cited in the application * |
VAN NESS J ET AL: "A VERSATILE SOLID SUPPORT SYSTEM FOR OLIGODEOXYNUCLEOTIDE PROBE -BASED HYBRIDIZATION ASSAYS" NUCLEIC ACIDS RESEARCH, vol. 19, no. 12, 25 June 1991 (1991-06-25), pages 3345-3350, XP000208399 ISSN: 0305-1048 * |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458530B1 (en) | 1996-04-04 | 2002-10-01 | Affymetrix Inc. | Selecting tag nucleic acids |
WO2000055363A3 (en) * | 1999-03-12 | 2000-12-21 | Amersham Pharm Biotech Uk Ltd | Analysis of differential gene expression |
WO2000055363A2 (en) * | 1999-03-12 | 2000-09-21 | Amersham Pharmacia Biotech Uk Ltd | Analysis of differential gene expression |
EP1200820A4 (en) * | 1999-07-16 | 2006-08-23 | Rosetta Inpharmatics Inc | Iterative probe design and detailed expression profiling with flexible in-situ synthesis arrays |
EP1200820A2 (en) * | 1999-07-16 | 2002-05-02 | Rosetta Inpharmatics Inc. | Iterative probe design and detailed expression profiling with flexible in-situ synthesis arrays |
AU761985B2 (en) * | 1999-07-20 | 2003-06-12 | Affibody Ab | In vitro selection and optional identification of polypeptides using solid support carriers |
WO2001005808A2 (en) * | 1999-07-20 | 2001-01-25 | Affibody Technology Sweden Ab | In vitro selection and optional identification of polypeptides using solid support carriers |
WO2001005808A3 (en) * | 1999-07-20 | 2001-08-02 | Affibody Technology Sweden Ab | In vitro selection and optional identification of polypeptides using solid support carriers |
US6955877B1 (en) | 1999-07-20 | 2005-10-18 | Affibody Ab | In vitro selection and optional identification of polypeptides using solid support carriers |
EP1191107A2 (en) * | 2000-09-25 | 2002-03-27 | Schering Aktiengesellschaft | Method for the in vitro diagnosis of endometriosis |
JP2002325600A (en) * | 2000-09-25 | 2002-11-12 | Schering Ag | Method for diagnosing heterotopic endometrio in vitro |
EP1191107A3 (en) * | 2000-09-25 | 2002-08-14 | Schering Aktiengesellschaft | Method for the in vitro diagnosis of endometriosis |
US6780594B2 (en) | 2000-09-25 | 2004-08-24 | Schering Aktiengesellschaft | Method for in vitro diagnosis of endometriosis |
WO2002027029A3 (en) * | 2000-09-27 | 2003-09-25 | Lynx Therapeutics Inc | Method for determining relative abundance of nucleic acid sequences |
US6897023B2 (en) | 2000-09-27 | 2005-05-24 | The Molecular Sciences Institute, Inc. | Method for determining relative abundance of nucleic acid sequences |
WO2002027029A2 (en) * | 2000-09-27 | 2002-04-04 | Lynx Therapeutics, Inc. | Method for determining relative abundance of nucleic acid sequences |
WO2002084283A2 (en) * | 2001-04-10 | 2002-10-24 | Nmi Naturwissenschaftliches Und Medizinisches Institut An Der Universität Tübingen In Reutlingen Stiftung Bürgerlichen Rechts | Method for determining analyte molecules in a sample |
WO2002084283A3 (en) * | 2001-04-10 | 2003-08-28 | Nmi Univ Tuebingen | Method for determining analyte molecules in a sample |
EP1425290A1 (en) * | 2001-08-14 | 2004-06-09 | Mount Sinai School of Medicine | Use of intrinsic reporters of cell signaling for high content durg profiling and toxicity screening |
EP1425290A4 (en) * | 2001-08-14 | 2007-06-06 | Sinai School Medicine | Use of intrinsic reporters of cell signaling for high content durg profiling and toxicity screening |
EP1786924A1 (en) * | 2004-07-06 | 2007-05-23 | Genera Biosystems Pty Ltd | Method of detecting aneuploidy |
EP1786924A4 (en) * | 2004-07-06 | 2008-10-01 | Genera Biosystems Pty Ltd | Method of detecting aneuploidy |
US7635566B2 (en) * | 2007-06-29 | 2009-12-22 | Population Genetics Technologies Ltd. | Methods and compositions for isolating nucleic acid sequence variants |
US8241850B2 (en) | 2007-06-29 | 2012-08-14 | Population Genetics Technologies Ltd. | Methods and compositions for isolating nucleic acid sequence variants |
WO2009114185A2 (en) | 2008-03-12 | 2009-09-17 | The Rockefeller University | Methods and compositions for translational profiling and molecular phenotyping |
EP3369827A1 (en) | 2008-03-12 | 2018-09-05 | The Rockefeller University | Methods and compositions for translational profiling and molecular phenotyping |
DE102021134368A1 (en) | 2021-12-22 | 2023-06-22 | Hochschule Reutlingen Körperschaft des öffentlichen Rechts | Device and method for detecting marked tumor cells of a tissue in a flowing liquid |
DE102021134368B4 (en) | 2021-12-22 | 2023-09-21 | Hochschule Reutlingen Körperschaft des öffentlichen Rechts | Device and method for detecting marked tumor cells of a tissue in a flowing liquid |
Also Published As
Publication number | Publication date |
---|---|
US6265163B1 (en) | 2001-07-24 |
AU754929B2 (en) | 2002-11-28 |
US6511802B1 (en) | 2003-01-28 |
NO20003531D0 (en) | 2000-07-07 |
KR100433782B1 (en) | 2004-06-04 |
KR20010033992A (en) | 2001-04-25 |
DE69930729D1 (en) | 2006-05-18 |
EP1054999B1 (en) | 2006-04-05 |
PL342114A1 (en) | 2001-05-21 |
NO20003531L (en) | 2000-09-05 |
ATE322556T1 (en) | 2006-04-15 |
CA2317695A1 (en) | 1999-07-15 |
EP1054999A2 (en) | 2000-11-29 |
WO1999035293A3 (en) | 1999-09-30 |
AU2113999A (en) | 1999-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6265163B1 (en) | Solid phase selection of differentially expressed genes | |
US6897023B2 (en) | Method for determining relative abundance of nucleic acid sequences | |
US5763175A (en) | Simultaneous sequencing of tagged polynucleotides | |
JP4124377B2 (en) | Sequencing by linking code adapters | |
US5962228A (en) | DNA extension and analysis with rolling primers | |
US20030049599A1 (en) | Methods for negative selections under solid supports | |
US20020172965A1 (en) | Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom | |
WO1997032999A1 (en) | Simultaneous sequencing of tagged polynucleotides | |
US20060199198A1 (en) | Polymorphic DNA fragments and uses thereof | |
AU2741899A (en) | Method of identifying gene transcription patterns | |
KR20210104555A (en) | Primer oligonucleotides for sequencing | |
EP1497465B1 (en) | Constant length signatures for parallel sequencing of polynucleotides | |
JP4344086B2 (en) | Solid phase selection of differentially expressed genes | |
US20030032020A1 (en) | Polymorphic DNA fragments and uses thereof | |
EP0840803B1 (en) | Simultaneous sequencing of tagged polynucleotides | |
CZ20002545A3 (en) | Selection of solid phase from differently exprimed genes | |
Nygaard et al. | Cell sampling and global nucleic acid amplification | |
JPH11151092A (en) | Extension of dna and assay by using rolling primer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999901448 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2317695 Country of ref document: CA Ref country code: CA Ref document number: 2317695 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-2545 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007007585 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 527674 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 21139/99 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999901448 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-2545 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007007585 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 21139/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007007585 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999901448 Country of ref document: EP |